Watch · 54/100 · medium confidence

The full analysis

IBEX Ltd (IBEX) — Council Assessment

🟡 WATCH · Score 54/100 · medium confidence

A cheaply-priced, cash-generative BPO with real growth momentum but a thin moat and a structural AI overhang that keeps it a Watch, not a Buy.

As of 2026-08-02. 19 lenses weighed in, 0 abstained. Sources: 6 filings, 11 news, 15 discussion, 1 earnings_call.

360 narrative — news & sentiment digest

IBEX Limited (IBEX) — Investment Briefing

Management Commentary (Q2 FY2026 Earnings Call, Feb 7, 2026)

Headline Results & Guidance

Q2 revenue: $164.2M (+16.7% YoY), marking fourth consecutive quarter of double-digit organic growth
Adjusted EPS: $0.87 (+46% YoY); GAAP EPS: $0.83 (+45% YoY)
Adjusted EBITDA: $20.7M (12.6% margin, +80 bps YoY)
Raised FY2026 guidance: Revenue now $620–630M (prior $605–620M); Adj. EBITDA $80–82M (prior $78–81M)
CapEx expected at upper end of $20–25M range to fund offshore expansion

Segment & Vertical Trends

HealthTech: +35.1% YoY, now 17.4% of revenue; on track to hit $100M run rate by year-end (launched 2021)
Travel/Transportation/Logistics: +20.2% YoY (14.1% of revenue)
Retail/E-commerce: stable at 28.6%, though management notes less seasonality from prior patterns as mix shifts away from legacy telecom
Telecom (legacy carriers): declined 23.1% YoY, now <10% of revenue for first time since pre-IPO
FinTech: flat at 9.3%, expected to grow in coming quarters
Digital/omni-channel services: +19% YoY, 82% of total revenue

Geography & Margin Drivers

Offshore revenue (52.3% of total): +16.2% YoY; highest-margin segment
Nearshore: +8.5% YoY
Onshore (digital acquisition services): +27.5% YoY, expanding to 24% of revenue (from 22%)
SG&A: 16.8% of revenue (down from 18.3%), showing operating leverage
Tax rate: 19.1% (vs. 20.2% prior year); expect 20–22% going forward (ex-discrete items)

Capital Allocation & Balance Sheet

Net cash position: $14.0M (up from $13.7M at FY-end)
Repurchased 78K shares ($2.9M) in Q2; 170K shares ($5.6M) YTD; $7.8M authorization remaining
Weighted avg. diluted shares: 14.7M (down from 16.5M YoY)
Free cash flow: –$5.1M in Q2 (outflow, due to seasonal CapEx; prior year –$3.2M)

AI & Strategic Positioning

Positioning "BPO 3.0" around WaveIX AI platform: (1) client-facing AI agents paired with human agents for seamless CX; (2) internal AI for agent hiring, training, onboarding ("speed to green"), operations optimization
Claims leadership position in AI deployments relative to competitors
Promoted Mike Darwall (10+ years with company) to Chief AI & Digital Officer; previously President of Digital and Deputy CFO
Appointed Jack Jones as new Chairman (ex-JPMorgan Chase, 26+ years as BPO buyer; also former exec at Expert Global Solutions)

Client Diversification

Top client: 10% of revenue (unchanged)
Top 10: 39%, Top 25: 79% (stable vs. prior year)
Notable: signature wins from FY25 already in top 20; FY24 wins in top 10
Strong retention track record over past decade

India Expansion

Entered late March 2025; now operating two sites with ~1,000 agents
Broadened beyond contact center into revenue cycle management and credentialing for healthcare clients
Described as "one of our highest growth vectors"
Still investing in margins; expansion fueled by both organic growth and new logo wins

Recent Developments

Q2 FY2026 earnings beat (Feb 7, 2026): Revenue $164.2M vs. consensus ~$161M; affirmed strong operational execution
Guidance raise (Feb 7): Full-year revenue +$10–15M midpoint; Adj. EBITDA +$1–2M midpoint
HealthTech vertical milestone: Expected to exceed $100M annual revenue by FY-end; has grown from launch in 2021
India market entry (Mar 2025): Two operational sites, ~1,000 agents; revenue cycle management capabilities added
Leadership changes (Feb 2026): Darwall elevated to Chief AI & Digital Officer; Jack Jones named Chairman
Multiple insider transactions (May–Jul 2026): Director sold 1,030 shares (May 29); Officer sold 3,600 shares at $30.61 (Jun 16); CEO withheld 4,511 shares on RSU vesting (Jul 6); transfer of 200 shares in divorce settlement (Jul 23)
Q3 FY2026 earnings beat (reported May 12, 2026): Stock surged ~15%; revenue beat expectations

Bull Narrative

Operational Momentum

Four consecutive quarters of double-digit organic growth, materially ahead of BPO peer group average (~5–8%)
Revenue growth (16–17% range) combined with expanding margins (EBITDA +80 bps YoY) demonstrates pricing power and operational leverage
SG&A declining as % of revenue (18.3% → 16.8%) despite rapid growth

Margin Expansion & Mix Tailwinds

High-margin verticals (HealthTech, digital services) growing faster than low-margin legacy telecom exposure
Offshore revenue growth (+16.2% YoY) at highest margins; mix shift away from onshore lower-margin work (though onshore digital is high-margin growth)
Management credibly attributing gross margin headwinds to temporary factors (deferred training revenue, early India ramp) rather than structural decay

AI Competitive Positioning

WaveIX platform claimed as industry-leading; dual benefits (client-facing agents + internal optimization) appear differentiated vs. pure-play contact center competitors
AI adoption resonating with trophy clients; new logo wins in HealthTech and FinTech attributed partly to AI differentiation
Early-mover advantage in AI-powered CX relative to larger, slower-moving competitors

Capital Allocation & Balance Sheet

Net cash of $14M, strong cash generation ($6.6M operating cash flow in Q2), enables organic investment
Disciplined share repurchase ($5.6M YTD) reducing share count 10% YoY; EPS leverage benefiting from buybacks at modest valuations

Market Positioning

Winning "trophy clients" from larger competitors; top 10 client growth +20% signals market share gains
Highly differentiated culture (world-class NPS scores, employee engagement) supporting retention and new client wins
Diversified client base (top 25 = 79% of revenue) reduces concentration risk

Visibility & Guidance Momentum

Raised full-year guidance twice (Q1 and Q2); pattern of conservative initial guidance and beat-and-raise suggests execution confidence
Strong H1 performance positioning well for H2; management tone confident on "second half and beyond"

Bear Narrative

Valuation Risk at Current Price

Stock price in mid-$30s (current $35.34) with FY2026 net income ~$48–50M implied (on $620–630M revenue, ~13% pre-tax margin); implies P/E ~16–17x, not cheap for a BPO operator
Retail commentary ("cheaper than dirt") contradicts current trading levels; valuation may have already priced in growth
Growth rate (16%) must sustain for years to justify multiples; BPO industry inherently cyclical

Execution Risk on AI Claims

WaveIX positioning and AI "leadership" claims are largely unverified; no quantified ROI disclosed for clients, only qualitative commentary
Risk that AI hype masks slower adoption, lower monetization, or commoditization as larger competitors (Atos, Accenture, etc.) deploy competing solutions
No clear evidence clients are paying premium pricing for AI; growth may be driven by traditional BPO volume, not AI upsell

Margin Expansion May Stall

Management cited temporary headwinds (deferred training revenue, India ramp); but these are growth investments that may not reverse quickly
Gross margins actually declined YoY (not disclosed explicitly, but implied by CFO commentary); could compress further if HealthTech/high-margin verticals hit saturation
Operating leverage from SG&A deleveraging is one-time; cannot sustain indefinitely

India & Offshore Expansion Execution Risk

Only 1.5 years into India (launched Mar 2025); two sites with ~1,000 agents is still small scale
Management notes India margins below expected levels; ramp could take years and capital may not materialize
Offshore labor arbitrage eroding globally as wage inflation spreads; India wage growth accelerating

Strategic Uncertainty & Insider Selling

Multiple insider transactions in May–Jul 2026 (officer, director, CEO RSU withholding) suggest opportunistic selling at current levels
CEO withholding shares on RSU vesting (Jul 6) is neutral-to-slightly-bearish signal relative to buyback discipline
Uncertainty around new Chairman and Chief AI officer appointments; track records with IBEX unproven (Jack Jones is external hire, though experienced)

Telecom Decline Risks

Telecom exposure fell from 13.1% to 8.7% YoY, but still material; "legacy carriers marking first time" <10% suggests contraction accelerating
If legacy telecom clients reduce spending further (likely in a recession), revenue could surprise to downside
Mix shift to HealthTech/higher-margin verticals makes company more exposed to healthcare spend volatility

Competitive Commoditization

Larger BPO peers (TTEC, Atos, Sykes) are also investing in AI; IBEX's claimed leadership may erode if competitors accelerate
"Trophy clients" with high outsourcing spend are likely to take competitive bids; retention risk if pricing power declines

Retail Sentiment

Overall Tone: Mixed-to-Bullish, with Conviction Clusters

Elliott Wave traders (@ElliottwaveForecast, multiple posts Jul–Aug 2026): Bullish technical posture; expect "new highs" from March 2026 lows, with 5-wave advance "nearly complete." Pattern suggests pullback to support zones ("blue boxes"), but bias remains upside; traders treating stock as part of broader risk-on rally.
Options/momentum traders (@SuperGreenToday, Jun 5): Bullish; Dec 2026 $30 calls positioned for +79% ROI; target zones suggest upside to mid-$30s.
Value-focused retail (@Landsman, May–Jul): Mixed; May commentary ("cheaper than dirt," valuation metrics imply undervaluation) vs. Jul note ("pivoted off low, target $37 by EOY") suggests updated sentiment as stock rallied; conviction moderate.
News aggregators/analysts (Globe and Mail, Investing.com): Positive framing of earnings beats and growth; Q3 "revenue beat, stock surges 15%" narrative amplifies bullish momentum.
Insider activity commentary (Stock Titan, Moomoo): Neutral-to-factual; insider sales noted without editorializing, but pattern of sales at $30–31 in Jun–Jul suggests some profit-taking at lower levels.

Conviction: Low-to-moderate. Retail excitement appears concentrated in technical traders and options players; fundamental value debate (cheap vs. fairly-valued) unresolved. No high-volume retail discussion boards surfaced in material.

Caveats

Limited primary sources: Single earnings call transcript (Feb 7, 2026) is only detailed management commentary. No Q3 transcript provided; references to Q3 earnings beat are from news headlines, not direct quotes. Management tone and specific guidance details in Q3 unknown.
Insider trading data incomplete: Multiple transactions noted, but no disclosure of insider motivations, blackout periods, or broader insider shareholding trends. Transactions too small to infer high conviction selling or

Bull case

IBEX earns strong returns on a light capital base (ROIC ~23.8%, ROE ~23.9% per fundamentals) achieved with minimal leverage (total liabilities $141.3M vs equity $154.5M, net cash ~$15.5M). It's undemanding on price (P/E 12.8x, P/S 0.85x), and the DCF base case of $43.23 vs $35.34 implies ~22% upside; the valuation referee and Greenblatt both pass it (72 and 74). Operationally, four consecutive quarters of double-digit organic growth, guidance raised twice to $620-630M revenue, HealthTech +35% YoY toward a $100M run rate, and disciplined buybacks reducing share count ~10% YoY all point to real, traceable earnings improvement (net income $13M FY2021 to $37M FY2025). The DCF's 4.24% FCF growth assumption sits well below the 16.7% recent revenue growth, implying conservatism if margins hold.

Bear case

This is a labor-arbitrage BPO with thin, fragile margins (operating 8.35%, FCF ~4.9%) and no durable moat — a scale-and-execution business, not a franchise. The single largest risk is AI: the core product (human-staffed tier-1 CX) is precisely what LLM/voice agents attack over a 3-10 year horizon, and WaveIX claims are entirely qualitative with zero quantified client ROI or pricing premium in any filing. Greenwald's EPV lands at ~$33-35 (roughly today's price), and 78% of the DCF sits in terminal value — the upside depends almost entirely on the business remaining viable post-disruption. The bear-case DCF ($33.67) is already below the current price, so downside protection is thin. Capex is accelerating ($8.9M FY2024 to $18.4M FY2025, nine-month FY2026 $24.6M), compressing near-term FCF to just $9.5M YTD. Client concentration (top 10 = 39%, top 25 = 79%) and insider selling into the rally add caution.

Dissent — where the council disagrees

The council splits along the growth-vs-moat axis. The Valuation Referee (72) and Greenblatt (74) are the only passes, resting on the 22% DCF discount and high ROIC/earnings yield. But their pass is directly contested by the AI/Disruption Referee (48) and Walter Schloss (32, high confidence) — Schloss flatly avoids on the absence of any tangible-asset floor (P/B 3.06x) and a price in the upper half of its range. Crucially, the Valuation Referee himself flags that his own WACC of 7.89% is too low for a company with Philippines/Pakistan/Nicaragua/Jamaica/India exposure, and that at 9-10% WACC the margin of safety evaporates — undercutting the very foundation of the pass. Greenwald's EPV (price already at intrinsic value) and the 78% terminal-value dependency corroborate the skeptics. The tension: the bulls are buying a cheap multiple on rising earnings; the bears note that a thin-moat business facing existential AI risk deserves a cheap multiple, and that the DCF discount is largely an artifact of an aggressive WACC.

Key risks

AI/LLM automation of tier-1 contact-center work structurally erodes the labor-arbitrage model over 3-10 years; WaveIX is unquantified marketing, not a proven moat
DCF is fragile: 78% terminal value, WACC likely understated at 7.89% (country risk unaccounted); at 9-10% WACC the stock is roughly fairly valued and bear case ($33.67) is already below price
Thin margins (8.35% operating, ~4.9% FCF) leave little buffer against offshore wage inflation or client pricing pressure
Accelerating capex ($24.6M nine-month FY2026) compressing near-term FCF to $9.5M YTD
Client concentration (top 10 = 39%, top 25 = 79%); loss of an anchor client materially impairs the thesis
Related-party history: $70M TRGI buyback and $1.1M related-party asset impairment; Bermuda incorporation limits shareholder-rights tools
Insider selling pattern May-July 2026 with no offsetting insider buying at prices management calls undervalued

Catalysts

Continued beat-and-raise on guidance and sustained double-digit organic growth
HealthTech vertical reaching $100M run rate and India expansion turning margin-accretive
Quantified evidence that WaveIX drives pricing premiums or net-new AI-attributable wins (would materially de-risk the moat)
Continued accretive buybacks reducing share count
Potential take-private: at ~$80-82M guided EBITDA, a 7-8x multiple implies $560-656M EV vs ~$458M current

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $43.23/share vs price $35.34 → +22% (bear $33.67 · base $43.23 · bull $56.25).

Step	Value
Base free cash flow	$27M
FCF growth (yrs 1-5)	4.2% (revenue CAGR)
WACC (β 0.718)	7.9%
Terminal growth	2.5%
PV of explicit FCF	$123M
PV of terminal (residual) value	$437M (78% of EV)
Enterprise value	$560M
less Net debt	$-15M
= Equity value	$576M
/ Shares (13M) = intrinsic/share	$43.23

Short-sell evaluation

🚫 AVOID SHORTING

IBEX is a poor short despite a contested moat and AI overhang. It is profitable, net-cash, cash-generative with OCF exceeding net income (a passing accrual test), trades at an undemanding 12.8x P/E and 0.85x sales, is executing accretive buybacks, and shows accelerating organic growth with raised guidance — none of the markers (overvaluation, deteriorating fundamentals, leverage, accounting fraud) that make shorts work. The AI disruption thesis is real but slow-moving and multi-year; there is no near-term catalyst to force a rerating down. Combined with a tiny ~13.3M-share float that makes borrow costly and squeeze risk acute, plus positive price momentum, the risk/reward for a short is unattractive. This is a Watch on the long side and an Avoid on the short side — a specialist-only, catalyst-dependent bear thesis at best.

Pros (the short could work)

Structural AI disruption risk to core tier-1 CX labor model over 3-10 years
Thin, fragile margins (8.35% operating, ~4.9% FCF) with limited buffer
78% terminal-value-dependent DCF with likely understated WACC; near fair value under realistic assumptions
Accelerating capex compressing near-term FCF; nine-month FY2026 FCF only $9.5M
Client concentration and legacy telecom decline (-23% YoY) create revenue air-pocket risk
Insider selling into the rally

Cons (what kills the short)

Profitable, net-cash balance sheet with OCF > net income — no distress or accrual red flag
Cheap valuation (P/E 12.8x, P/S 0.85x) already prices in skepticism; limited downside from a low base
Accelerating organic growth (16.7% YoY), guidance raised twice — improving, not deteriorating, fundamentals
Tiny ~13.3M-share float makes borrow expensive and squeeze risk high
Ongoing accretive buybacks (~10% YoY share reduction) and positive price momentum
Possible take-private optionality at 7-8x EBITDA provides upside risk to shorts

Council scorecard

Lens	School	Stance	Score	Conf
Joel Greenblatt	value	🟢 pass	74	medium
Valuation Referee (Damodaran-style)	referee	🟢 pass	72	medium
Peter Lynch	growth	🟡 watch	58	medium
Ray Dalio	risk	🟡 watch	55	medium
Bruce Greenwald	value	🟡 watch	55	medium
Howard Marks	risk	🟡 watch	55	medium
Michael Mauboussin	quality	🟡 watch	55	medium
Chuck Akre	quality	🟡 watch	52	medium
Warren Buffett	quality	🟡 watch	52	medium
Stanley Druckenmiller	risk	🟡 watch	52	medium
Philip Fisher	growth	🟡 watch	52	medium
Benjamin Graham	value	🟡 watch	52	medium
Seth Klarman	value	🟡 watch	52	medium
Charlie Munger	quality	🟡 watch	52	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟡 watch	52	medium
Paul Singer	value	🟡 watch	52	medium
Terry Smith (Fundsmith)	quality	🟡 watch	52	medium
AI & Disruption Referee (Christensen-style)	referee	🟡 watch	48	medium
Walter Schloss	value	🔴 avoid	32	high

Member reasoning

Joel Greenblatt — 🟢 pass · 74/100 · medium confidence

IBEX passes the Magic Formula test on both axes at current prices, though not with spectacular margins. On ROIC (Greenblatt's preferred tangible-capital definition): EBIT for FY2025 was $46.6M (10-K filed 2025-09-11). Net working capital = current assets ($158.5M) minus current liabilities ($86.5M) = $72.0M. Net fixed assets are not separately disclosed in the excerpts available, but total assets of $295.8M minus current assets of $158.5M = $137.3M non-current assets, of which a meaningful portion is operating lease ROU assets and PP&E — the fact base does not isolate net PP&E precisely, but capex of $18.4M and a depreciation-heavy services business suggests a relatively modest tangible fixed-asset base. Using a conservative estimate of ~$50–60M net PP&E (which may overstate given the offshore delivery model), Greenblatt ROIC = $46.6M / ($72M + $55M) ≈ 37%, which is high and indicative of a capital-light, high-quality business. Even if net fixed assets are $80M, ROIC ≈ 31% — still strong. On earnings yield: Market cap ~$473M. Cash $15.5M with no explicit total debt figure available in the fact base (debt_to_equity reported as null; the 10-Q references HSBC Credit Facilities with net draws but no balance disclosed). The valuation block uses net_debt of -$15.5M (net cash), implying EV ≈ $473M - $15.5M = ~$457M. EBIT/EV = $46.6M / $457M ≈ 10.2% earnings yield — solidly attractive by Magic Formula standards (Greenblatt's threshold is typically 7–10%+ for a buy signal). The combination of ~30%+ ROIC and ~10% earnings yield ranks favorably. The business is also genuinely capital-light: offshore BPO delivery centers with modest fixed assets, predominantly people-based cost structure, and proven FCF conversion (FY2025 FCF $27.3M, operating cash $45.7M per the 10-K). Revenue CAGR of 4.2% over 3 years is modest but FY2025 growth accelerated to ~10% and the narrative (Q2 FY2026 earnings call) describes four consecutive quarters of double-digit organic growth with raised guidance to $620-630M. Concerns: (1) Total debt balance is not clearly stated in filings excerpts — HSBC Credit Facilities are mentioned with 'net draws' language but no outstanding balance, which is a material gap for precise EV calculation; if debt is material, earnings yield compresses. (2) The 10-Q (filed 2026-02-05) shows elevated H1 FY2026 capex of $19.4M in just six months vs. $18.4M for all of FY2025, driven by offshore expansion and India ramp — this is a temporary FCF headwind that doesn't impair EBIT-based ROIC but does reduce near-term cash conversion. (3) No special-situation catalyst is present; this is a straight Magic Formula play. (4) AI disruption risk is real but cuts both ways — the WaveIX positioning and offshore labor arbitrage could be eroded by AI automation of voice/chat CX, but IBEX is actively embedding AI into its delivery model (per Q2 FY2026 earnings call narrative). The commodity risk is real over a 5-10 year horizon; a BPO operator's moat is thinner than a software business. On balance, a good business at a fair-to-cheap price: pass with moderate conviction.

Key points

EBIT of $46.6M (FY2025 10-K) on a modest tangible capital base implies Greenblatt ROIC of ~30-37%, well above typical Magic Formula thresholds
Earnings yield EBIT/EV approximately 10.2% using net cash position of $15.5M (valuation block) — attractive on an enterprise basis
Capital-light offshore BPO model (Philippines, Pakistan, Nicaragua, Jamaica per 10-Q filings) structurally supports high tangible ROIC
FCF of $27.3M in FY2025 (10-K) demonstrates real cash conversion; operating cash flow $45.7M shows EBIT quality
Revenue accelerating to double-digit growth (four consecutive quarters per Q2 FY2026 earnings call); raised FY2026 guidance to $620-630M
Share count reduced materially — 3.56M shares repurchased via TRGI Purchase Agreement at $70M aggregate (10-K 2025), plus ongoing buyback programs; diluted shares down ~10% YoY
P/E of 12.8x and price-to-sales of 0.85x (fundamentals block) are undemanding for a business with 23.9% ROE and accelerating growth

Red flags

Total debt balance not explicitly stated in filing excerpts — HSBC Credit Facilities referenced with 'net draws' language but no outstanding balance disclosed, creating uncertainty in precise EV and earnings yield calculation
H1 FY2026 capex of $19.4M already exceeds full FY2025 capex of $18.4M (10-Q filed 2026-02-05), suppressing near-term FCF; management guides to upper end of $20-25M full-year range
AI/automation risk: BPO voice and chat CX is a primary target for AI displacement over 3-10 years; WaveIX claims are qualitative and unquantified in the filings
No special-situation catalyst — this is a vanilla Magic Formula play; discount may close slowly or not at all without a corporate event
Insider selling pattern (officer sold 3,600 shares at $30.61, director sold 1,030 shares per narrative) at prices below current $35.34 is mildly negative signal, though RSU withholding by CEO is mechanical not discretionary
Legacy telecom vertical declining 23.1% YoY (now <10% of revenue per Q2 call) — continued erosion could create near-term revenue headwind despite mix shift

Valuation Referee (Damodaran-style) — 🟢 pass · 72/100 · medium confidence

IBEX trades at $35.34 against a base-case DCF intrinsic value of $43.23, implying ~22% upside on the model's assumptions. The key question is whether those assumptions are defensible or heroic. I judge them modestly favorable but not without risk, landing the score at 72 — a clear but not emphatic pass.

DCF inputs audit: The model uses base FCF of $27.3M (FY2025 actual, per 10-K filed 2025-09-11), a revenue CAGR of 4.24% applied as FCF growth, WACC of 7.89% (beta 0.718, no debt adjustment since debt-to-equity is null per fundamentals), and terminal growth of 2.5%. Terminal value is $638.8M PV'd to $437M, representing 78% of equity value — a high but typical BPO proportion. Let me reverse-engineer what the current $35.34 price requires vs. what the $43.23 base implies.

Implied expectations at current price: At $35.34, the market is essentially pricing IBEX at roughly the bear case ($33.67 per sensitivity). That bear case likely embeds slower FCF growth or higher discount rates. Given the 10-K confirms FY2025 operating cash flow of $45.7M and capex of $18.4M yielding $27.3M FCF, and the Q2 FY2026 narrative (management commentary) cites raised full-year revenue guidance to $620-630M with Adj. EBITDA $80-82M, the market appears to be pricing in stagnation rather than the 9-month trajectory showing $34.2M operating cash flow vs. $17.7M prior year (10-Q filed 2026-05-06). This is the core margin of safety argument: the price implies bearish expectations that appear inconsistent with observable trailing-twelve-month momentum.

ROIC vs. WACC — growth quality test: Fundamentals show ROIC of 23.8% against an implied WACC of ~7.9%. This is a substantial spread, meaning incremental investment is genuinely value-creating. FCF has grown from -$4.7M (2021) to $27.3M (2025) while revenue grew from $443M to $558M — a sales-to-capital ratio that appears reasonable for a labor-intensive BPO. Capex stepped up to $18.4M in FY2025 (vs. $8.9M prior year, per 10-K) to fund offshore expansion (India, per narrative); this is reinvestment supporting the growth story, not value destruction.

Margin trajectory: Operating margin is 8.35%, net margin 6.6%, FCF margin 4.89% (FY2025). These are thin by software standards but typical for offshore BPO. Adjusted EBITDA margin of 12.9% (10-K) is consistent with peers. The narrative confirms SG&A declining as % of revenue (18.3% → 16.8% YoY), and offshore revenue mix increasing — both structural tailwinds to margin expansion. The DCF's 4.24% FCF growth assumption is BELOW the 16.7% revenue growth cited in Q2 FY2026 earnings, suggesting meaningful conservatism if margins hold or expand.

WACC critique: 7.89% WACC with beta 0.718 is low for a company with significant offshore operations in Philippines, Pakistan, Nicaragua, Jamaica (all cited in 10-Q filed 2026-05-06) and India. Country risk premia should arguably add 100-150 bps. A more defensible WACC of 9-10% would compress intrinsic value materially — the bear sensitivity ($33.67) may approximate this. At 9.5% WACC, the stock looks closer to fairly valued than discounted. This is the key risk to the pass verdict.

Terminal value concentration: 78% of equity value in terminal value is high. Terminal growth of 2.5% is at the upper bound of defensible (roughly nominal GDP for a global services firm). If terminal growth were 2.0% and WACC 9%, intrinsic value would likely fall to the $30-35 range — eliminating the margin of safety. This is a legitimate concern.

AI disruption: The WaveIX narrative (earnings call) positions IBEX as an AI-enhanced BPO operator. From a valuation perspective, the question is whether AI is a margin enhancer (credible, as internal automation improves agent productivity per management commentary) or an existential threat (AI agents replacing human agents). The honest answer: over 3-5 years AI is likely margin-neutral to slightly positive for IBEX as it uses AI to differentiate; over 7-10 years the risk of AI commoditizing human-agent contact center work is real and meaningful. The DCF does not explicitly model an AI-disruption scenario, which means the terminal value may be optimistic if AI compresses BPO pricing power by 2030+. This is a watch-level concern embedded in the confidence level rather than a pass-blocker at current price.

Story-to-numbers consistency: The bull narrative (HealthTech vertical growing 35% YoY, offshore mix shift, AI positioning) IS reflected in improving numbers — revenue +9.8% FY2025, operating income growing, ROIC at 23.8%, FCF stable. This is not a story disconnected from numbers. The 4.24% DCF growth assumption appears beatable given current trajectory, which is a positive for the margin of safety.

Verdict summary: At $35.34, the stock sits ~22% below the base DCF and near the bear case. The bear case requires either WACC materially above 7.89% (plausible) or FCF growth below 4.24% (implausible given current momentum). On balance, current price offers a modest but real margin of safety under fair assumptions. I score 72: a pass, but confidence is medium because WACC assumptions need scrutiny and AI-disruption tail risk in the terminal period is underweighted.

Key points

Base DCF of $43.23 vs. $35.34 price implies ~22% upside; current price approximates the bear-case sensitivity ($33.67), suggesting market prices in pessimistic assumptions inconsistent with observable momentum
ROIC of 23.8% vs. WACC ~7.89% indicates value-creating reinvestment; FCF growth from -$4.7M (2021) to $27.3M (2025) with sales-to-capital ratio plausible for offshore BPO expansion (10-K FY2025)
DCF FCF growth assumption of 4.24% is well below Q2 FY2026 revenue growth of 16.7% (per management commentary), implying meaningful conservatism in the model if margins hold
SG&A declining as % of revenue (18.3% to 16.8%, per Q2 FY2026 narrative) and offshore mix shift are structural margin tailwinds that support the FCF growth story
Revenue guidance raised twice (Q1 and Q2 FY2026) to $620-630M; 9-month operating cash flow of $34.2M vs. $17.7M prior year (10-Q filed 2026-05-06) indicates the FCF base may be understated
Share count declining (diluted shares down from 16.5M to 14.7M YoY per narrative) via buybacks adds per-share FCF accretion not captured in entity-level DCF

Red flags

WACC of 7.89% may be too low for a company with material operations in Philippines, Pakistan, Nicaragua, Jamaica, and India — each carrying sovereign/currency risk; a 9-10% WACC erases most of the margin of safety
Terminal value represents 78% of equity value with 2.5% terminal growth at the upper bound of defensible; a 50 bps haircut to terminal growth with higher WACC could push intrinsic value below current price
AI disruption risk over 7-10 year horizon is real: if AI agents commoditize human-agent BPO work, the terminal value assumptions (stable margins, perpetual growth) are optimistic — this risk is structurally underweighted in any standard DCF
Q2 FY2026 capex running at upper end of $20-25M guidance range (10-Q shows $24.6M capex for 9 months ended March 2026 vs. $13.2M prior year), suggesting FCF may be pressured in near term even as operating cash flow improves
Multiple insider sales in May-July 2026 (officer sold 3,600 shares at $30.61, director sold 1,030 shares per narrative) at prices below current $35.34 are not alarming individually but warrant monitoring as a sentiment signal
Debt-to-equity is null in fundamentals data — credit facility draws of $19.1M noted in 10-Q; full capital structure and covenant details are missing from the fact base, preventing a complete WACC build

Peter Lynch — 🟡 watch · 58/100 · medium confidence

IBEX is a BPO (business process outsourcing) company — explainable in one sentence: it runs offshore/nearshore contact centers and digital acquisition services for U.S. clients, primarily in HealthTech, Retail/e-commerce, and Travel verticals. The earnings story is real and traceable: net income has grown from $13M (FY2021) to $37M (FY2025) per the fundamentals history, and the Q2 FY2026 earnings call (Feb 7, 2026) cited four consecutive quarters of double-digit organic revenue growth with raised full-year guidance to $620–630M. That is a genuine growth trajectory. However, the PEG is the show-stopper here. The fundamentals block reports a PEG of 3.03 — well above my 1.0 threshold and deep into 'overpaying' territory. The 3-year revenue CAGR is only 4.24% (fundamentals), and while EPS growth has been faster (net income roughly tripled over four years from FY2021 baseline, but the FY2021 base was depressed at $13M), the forward EPS growth rate implied by a 16–17% revenue run rate does not fully repair the PEG at current prices because the P/E of ~12.8x is not low enough to offset middling reported growth rates used in the PEG calculation. The stock is best categorized as a 'fast grower' transitioning — HealthTech (+35% YoY), digital services (+19% YoY), and India expansion are all growth vectors. But the overall business still has legacy telecom drag (declined 23.1% YoY per narrative), and the 3-year revenue CAGR of 4.24% is stalwart-pace, not fast-grower pace. That mismatch matters: I price fast growers on fast-grower PEGs; if the actual CAGR is 4–5%, a PEG of 3+ at any P/E is hard to justify. Balance sheet is acceptable: current ratio of 1.83, stockholders' equity of $154.5M vs. total liabilities of $141.3M (10-Q filed 2026-02-05), and modest net cash of ~$15.5M (fundamentals). The TRGI share repurchase ($70M for 3.56M shares, paid $45M cash + $25M note per 10-K filed 2025-09-11) was a large related-party transaction that consumed cash and added temporary leverage — the convertible note was repaid Jan 2025, so that risk has passed, but it was a notable capital event. Buybacks are ongoing: the May 2026 8-K authorized a new $20M repurchase program; the 2025 program was nearly exhausted ($3.2M remaining as of March 31, 2026 per the 10-Q filed 2026-05-06). Insider activity is mixed — the narrative flags officer/director sales in May–Jul 2026 at $30–31, not strong conviction buying. On AI: the WaveIX platform and 'BPO 3.0' positioning are qualitative claims from the earnings call narrative with no quantified client ROI disclosed. AI is a legitimate threat to traditional BPO volume over a 3–10 year horizon (automated agents displacing human contact center agents), and IBEX's mitigation strategy — pairing AI agents with human agents — is logical but unproven at scale. The India expansion and HealthTech ramp are genuine growth vectors but still early-stage (India: ~1,000 agents, launched March 2025). Free cash flow has been inconsistent intra-year (Q2 FY2026: –$5.1M due to capex per 10-Q filed 2026-05-06; full-year FY2025: $27.3M per 10-K filed 2025-09-11), and capex is rising (FY2025: $18.4M vs. FY2024: $8.9M). The DCF shows 22% upside to $43.23 base case, which is supportive but not a deep margin of safety. At ~$35, the stock is not 'cheaper than dirt' on my PEG discipline — I want PEG ≤1, and I am not seeing that here. It's a watch: real growth story, improving margins (Adj. EBITDA margin 12.9% per 10-K filed 2025-09-11), but the PEG is too stretched for a conviction buy.

Key points

Category: transitional fast-grower with stalwart-pace overall CAGR — HealthTech (+35% YoY), digital (+19%) are fast-growth sub-segments, but total 3-year revenue CAGR of 4.24% (fundamentals) blends them down
PEG of 3.03 (fundamentals) is far above my 1.0 threshold; P/E of 12.8x is not low enough to compensate given the reported growth rate inputs
Earnings growth is real: net income $13M (FY2021) → $37M (FY2025) per history, and Q2 FY2026 adjusted EPS +46% YoY (narrative) shows acceleration — but acceleration must sustain to fix the PEG
Balance sheet manageable: current ratio 1.83, net cash ~$15.5M, TRGI convertible note repaid January 2025 (10-K filed 2025-09-11); no looming maturities flagged
Share buybacks are shareholder-friendly: $20M new program authorized May 2026 (8-K filed 2026-05-13), share count down ~10% YoY (narrative); aligns with Lynch buyback positive signal
Offshore/nearshore mix shift and SG&A leverage (18.3% → 16.8% of revenue per narrative) are genuine margin drivers, not accounting tricks
HealthTech vertical ($100M run rate by FY-end) and India expansion (RCM + credentialing capabilities) are explainable, repeatable growth levers — the 'roll-out' formula I look for
DCF intrinsic value $43.23 vs. $35.34 current price (22% upside, base case) provides moderate margin of safety — not deep, but not zero

Red flags

PEG of 3.03 is the primary disqualifier for a conviction buy under my framework — well above the 1.0 threshold and approaching 'hot stock' territory
AI displacement risk to core BPO volume is real over a 3–10 year horizon; WaveIX claims are qualitative only — no client ROI data in the fact base to verify differentiation
TRGI Purchase Agreement ($70M buyback of 3.56M shares from controlling shareholder, 10-K filed 2025-09-11) was a large, unusual related-party transaction — governance optics are not ideal for a Lynch-style 'boring company'
Insider selling: officer sold 3,600 shares at $30.61 (Jun 2026), director sold 1,030 shares (May 2026) per narrative — not catastrophic, but lacks the insider buying signal I prefer
Capex jumped from $8.9M (FY2024) to $18.4M (FY2025) and is guided to $20–25M in FY2026 (narrative), compressing FCF margins just as revenue accelerates — capital intensity rising
Legacy telecom decline (–23.1% YoY, now <10% of revenue per narrative) is a drag that could surprise further to downside if carriers cut outsourcing budgets
India expansion margins below expected levels (management commentary in narrative) — early-stage ramp consuming capital without near-term margin contribution
Free cash flow intra-year volatility (10-Q filed 2026-05-06 shows nine-month FCF of only $9.5M vs. $4.5M prior year) makes FCF-based valuation less reliable; seasonal capex patterns distort quarterly reads

Ray Dalio — 🟡 watch · 55/100 · medium confidence

IBEX Limited is a BPO/contact-center operator with meaningful multi-regime relevance but also notable single-regime dependencies. Working through Dalio's four-box framework: (1) RISING GROWTH / FALLING INFLATION (boom): IBEX clearly wins here — double-digit organic revenue growth, expanding margins, offshore mix shift, HealthTech ramp. (2) RISING GROWTH / RISING INFLATION (reflation): Partial resilience. USD-priced contracts with offshore delivery in PHP, PKR, NIO, JMD means cost inflation in those currencies hurts margins — the 10-K and 10-Q filings confirm substantial PHP exposure hedged via collar contracts (notional $88.9M, 10-K filed 2025-09-11), but only for 1-18 months at a time. Beyond the hedge tenor, inflation in offshore labor markets (particularly Philippines wage growth) could compress margins without compensatory pricing power; BPO contracts tend to be multi-year at negotiated rates, limiting pass-through. (3) FALLING GROWTH / FALLING INFLATION (deflationary bust): Moderate resilience. Demand for outsourced CX is somewhat countercyclical — corporate cost-cutting pressures drive BPO adoption — but client discretionary spending cuts (particularly in HealthTech, FinTech, and retail/e-commerce verticals) could reduce volumes. The telecom vertical's secular decline (now <10% of revenue per Q2 FY2026 narrative) shows some clients do pull back. Revenue CAGR is only ~4.2% over 3 years (fundamentals block), suggesting modest through-cycle durability. (4) RISING INFLATION / FALLING GROWTH (stagflation): This is the most dangerous regime for IBEX. Offshore labor cost inflation without pricing power, combined with client volume reductions, would squeeze both revenue and margins simultaneously. FCF margin is already thin (4.9% in FY2025 per fundamentals). BALANCE SHEET: Net cash position is modest but positive (~$15.5M cash, debt-to-equity not disclosed in fundamentals block but total liabilities $141.3M vs. stockholders' equity $154.5M as of 2025-12-31 per 10-Q filed 2026-02-05). The 10-Q references HSBC Credit Facilities with net draws of $19.1M (10-Q filed 2026-05-06) and $7.5M (10-Q filed 2026-02-05) — floating-rate bank credit introduces rate sensitivity, though absolute debt levels appear modest relative to operating cash flow (~$45.7M in FY2025 per 10-K filed 2025-09-11). No maturity wall detail is available in the fact base to fully stress-test. Interest coverage is not explicitly stated but operating income of $46.6M vs. implied modest interest expense (interest expense was $0.5M in FY2024 per 10-K filed 2024-09-12) suggests no near-term distress. DEBT CYCLE: IBEX's clients span HealthTech, retail/e-commerce, and FinTech — consumer-facing sectors with moderate credit-cycle sensitivity. However, IBEX itself is not a leveraged credit story; it is a services business funded by operating cash flows with minimal CapEx intensity (capex $18.4M vs. OCF $45.7M in FY2025). The TRGI share repurchase ($70M including a $25M convertible promissory note repaid January 2025 per 10-K filed 2025-09-11) was a temporary leverage event, now resolved. The new $20M buyback (8-K filed 2026-05-13) is funded from cash — not debt — which is prudent. RATE SENSITIVITY: Floating-rate HSBC facility creates some exposure to sustained higher rates, but given low absolute debt levels and strong OCF, this is not a Dalio-scale red flag. Demand for BPO services is not financing-cost-dependent in the way housing or autos are. FX/GEOGRAPHIC DIVERSIFICATION: This is a genuine positive through the Dalio lens. Revenue is USD-denominated but delivery is multi-geography (Philippines, Pakistan, Nicaragua, Jamaica, and now India per narrative). This creates a natural short in EM currencies relative to USD revenues — a hedge against USD strength scenarios. However, a sharp EM currency appreciation (e.g. PHP strengthening) would compress margins, as costs rise in USD terms. The collar hedging program partially addresses this. CORRELATION/DIVERSIFICATION VALUE: Low beta (0.72 per fundamentals) suggests below-market correlation to equities — a meaningful positive for portfolio construction. BPO demand drivers (corporate outsourcing decisions, offshore labor arbitrage, CX technology adoption) are partially decoupled from pure equity market drivers. AI RISK (3-10 year horizon): This is the most material long-term threat from a Dalio perspective. If AI agents substantially automate voice and digital CX — the core IBEX service — the labor-arbitrage model faces structural disruption. IBEX's WaveIX positioning (narrative) is a forward hedge, but the fact base contains no quantified evidence of revenue generated from AI services, client ROI data, or premium pricing. The risk that larger AI-native competitors commoditize the space is real and could impair FCF durability across all four regimes — a true regime-independent tail risk. VALUATION: The DCF base case yields $43.23/share (22% upside vs. $35.34 current price), using 4.2% FCF growth and 7.9% WACC. The terminal value represents 78% of enterprise value (valuation block) — a high residual dependency that assumes the current regime persists. In a stagflation or deflationary bust scenario where FCF growth stalls, intrinsic value could approach the bear case of $33.67 (below current price). The P/E of 12.8x and P/S of 0.85x are modest, providing some cushion, but FCF yield of ~5.8% ($27.3M FCF / $473M market cap) is not a margin-of-safety bargain for a cyclically exposed service business. OVERALL: IBEX is not a Dalio-style high-conviction hold — it lacks the regime robustness, real-asset backing, and explicit inflation pass-through mechanisms Dalio rewards. But it avoids the worst red flags: balance sheet is self-funding, debt is low, beta is below 1, and geographic diversification is genuine. It earns a 'watch' rather than 'avoid' because the macro risks are manageable rather than existential at current leverage levels, but a regime shift to stagflation or an AI disruption scenario would materially impair the thesis.

Key points

Net cash positive balance sheet (~$15.5M cash per 2025-12-31 10-Q) with no evident maturity wall — passes the self-funding test for a downturn scenario
Low beta of 0.72 (fundamentals block) offers genuine below-market correlation, adding diversification value per Dalio's Holy Grail framework
Multi-currency delivery (PHP, PKR, NIO, JMD, INR) with USD-priced revenues creates a structural FX diversification — natural hedge to USD strength scenarios
PHP collar hedging program (notional $88.9M per 10-K filed 2025-09-11) mitigates near-term offshore inflation pass-through risk, though only for 1-18 month tenor
Free cash flow consistently positive and growing ($22.9M → $27.0M → $27.3M FY2023-2025 per fundamentals) — demonstrates through-cycle durability so far
Moderate revenue diversification across verticals (HealthTech 17%, Retail 29%, Travel 14%, FinTech 9%) reduces single-client/sector concentration risk
TRGI convertible promissory note ($25M) was repaid January 2025 (10-K filed 2025-09-11) — temporary leverage event resolved cleanly

Red flags

Terminal value represents 78% of DCF enterprise value (valuation block) — intrinsic value is highly sensitive to regime persistence; bear case ($33.67) is already below current price of $35.34
Stagflation scenario is the critical vulnerability: USD cost inflation in offshore labor markets (beyond 18-month hedge window) combined with client volume cuts would simultaneously pressure revenue and margins, with limited pricing power in multi-year BPO contracts
Floating-rate HSBC Credit Facilities (referenced in 10-Q filed 2026-05-06 and 2026-02-05) introduce rate sensitivity, though absolute debt levels appear modest — full terms and maturity schedule not available in fact base
AI disruption is a regime-independent structural tail risk: if AI agents commoditize voice/digital CX, IBEX's labor-arbitrage model faces impairment across all four Dalio regime boxes — WaveIX claims are unquantified in the fact base
FCF margin is thin at 4.9% (FY2025, fundamentals) — limited buffer to absorb simultaneous revenue contraction and cost inflation in a stagflation scenario
CapEx is accelerating (from $8.9M in FY2024 to $18.4M in FY2025 to expected $20-25M in FY2026 per narrative) — reduces FCF headroom during an expansion cycle that could reverse in a downturn
Insider selling pattern (officer sold 3,600 shares at $30.61 June 2026, director sold 1,030 shares May 2026 per narrative) at lower prices than current, though volumes are small and insufficient to draw strong conclusions

Bruce Greenwald — 🟡 watch · 55/100 · medium confidence

IBEX is a BPO/contact center operator with real operating history and normalizable earnings — the Greenwald methodology applies cleanly. The key value question is: does EPV exceed asset reproduction value (franchise), and does the market price sit below EPV (margin of safety)?

EPV Calculation (normalized): Using the 10-K (filed 2025-09-11, period 2025-06-30): operating income = $46.6M, operating margin = 8.35% on $558M revenue. This is a cyclically higher year (revenue grew from $508M in FY2024 back to $558M). Averaging operating margins over the 5-year history: net income went from $13M (2021) to $37M (2025) — margins clearly improved, partly structural (mix shift offshore), partly cyclical recovery. I'll use a normalized operating income closer to the 4-year average excluding the depressed 2021: roughly $40–45M EBIT is defensible. Tax-affecting at ~20% (effective rate per 10-K FY2024 was 17.9%; management guides 20–22% going forward per narrative): NOPAT ≈ $34–36M. Now adjust for maintenance capex vs. D&A: capex was $18.4M in FY2025 vs. $8.9M in FY2024 — management explicitly states in the 10-Q (filed 2026-02-05) that the FY2026 capex uplift is driven by offshore expansion investment, i.e., growth capex. Maintenance capex is probably closer to $9–12M (FY2024 level), with D&A likely similar or slightly above. No material excess D&A cushion to add back. So adjusted distributable earnings ≈ NOPAT ≈ $34–36M. Capitalizing at WACC of 7.89% (per the valuation block): EPV = $34–36M / 0.0789 ≈ $430–456M enterprise value. Adding net cash of ~$15M (10-Q Dec 2025 balance sheet): equity EPV ≈ $445–471M. Divided by ~13.3M shares outstanding: EPV per share ≈ $33–35. Current price is $35.34. The stock is trading essentially at EPV — little or no margin of safety on a no-growth conservative basis.

Asset Reproduction Value: Total assets = $296M (10-Q Dec 2025); liabilities = $141M; book equity = $155M. But reproduction value exceeds book: to rebuild IBEX's offshore delivery network (Philippines, Pakistan, Nicaragua, Jamaica, India — per 10-K and narrative), client relationships, brand in BPO, hiring/training infrastructure, and WaveIX platform, a competitor would need to spend materially more than book. Rough estimate: 1.5–2x book equity = $230–310M reproduction value. At market cap of $473M, the market is pricing EPV roughly at reproduction value or slightly above, implying a thin or contested moat.

Moat Assessment: EPV ($445–471M equity) is roughly in line with or slightly above reproduction value ($230–310M) — not strongly above it, which would signal a clear franchise. IBEX has some customer captivity (long-term contracts, deep client integrations, narrative cites 'strong retention track record'), but BPO is a competitive, low-barrier industry at a structural level. Scale economies exist within delivery centers (offshore labor arbitrage) but are replicable. The WaveIX AI platform is positioned as differentiating (narrative), but the claims are qualitative and unverified by disclosed client ROI or pricing premiums. No filing evidence of above-cost-of-capital returns sustained across a full cycle — ROIC of 23.8% (fundamentals block) is attractive but reflects a cyclical peak; mean reversion is the Greenwald default assumption absent a proven moat. The EPV≈reproduction value reading suggests a competitive business where growth is largely value-neutral unless the AI positioning delivers sustainable above-cost returns.

DCF Sanity Check: The provided DCF yields $43.23/share intrinsic value (22% upside). But 78% of that value sits in the terminal value (per valuation block: residual_value_pct=0.78). This is precisely the Greenwald red flag — the price is justified almost entirely by long-dated growth assumptions capitalized into a terminal value. The EPV calculation, which refuses to pay for growth, yields a figure essentially at the current price. I weight the EPV heavily over the DCF.

AI Disruption Assessment: AI is a double-edged sword for IBEX. As a contact center operator, AI agents could disintermediate human agents — the core labor product — over a 5–10 year horizon. IBEX's 'BPO 3.0' and WaveIX positioning (narrative) is an attempt to ride this wave rather than be crushed by it, but the risk that AI commoditizes basic CX work (Tier 1 support, simple queries) is real and structural. The company is betting on hybrid human+AI and on moving up the value chain (revenue cycle management, digital acquisition services). This is plausible but not yet demonstrated at scale, and it increases execution risk. From a Greenwald lens, technological disruption that erodes the labor-cost moat is a barrier-to-entry eroder, not a builder.

Summary: Stock trades at roughly EPV with no meaningful margin of safety. Moat evidence is thin — EPV does not clearly exceed reproduction value. Growth thesis depends on AI positioning and offshore expansion that is not yet proven. Capital allocation is reasonable (buybacks, net cash) but share count reduction from ~18M to 13.3M shares (per filings) partly explains EPS improvement, masking modest underlying earnings growth. Watch, not avoid — the business is real and improving — but not a Greenwald buy without a 15–20% pullback to create the required margin of safety below EPV.

Key points

EPV per share estimated at ~$33–35 (NOPAT ~$34–36M / WACC 7.89%), essentially equal to current price of $35.34 — zero margin of safety on a no-growth conservative basis
Asset reproduction value estimated at $230–310M equity (1.5–2x book of $155M per 10-Q Dec 2025); market cap of $473M is modestly above reproduction value, suggesting a thin or unproven franchise rather than a clear moat
ROIC of 23.8% (fundamentals) is attractive but likely cyclically elevated; Greenwald default is mean reversion to cost of capital absent demonstrated, durable barriers to entry
Revenue trajectory is improving (FY2024 $508M → FY2025 $558M → FY2026 guidance $620–630M per narrative), but 3-year revenue CAGR of only 4.24% (fundamentals block) shows the longer-term growth rate is modest
Provided DCF has 78% of value in terminal value (valuation block: residual_value_pct=0.78) — classic Greenwald red flag; the bull case depends almost entirely on far-future growth assumptions
Share count reduction from ~18M diluted shares (10-K FY2024) to ~13.3M (fundamentals block) is meaningful EPS tailwind but reflects capital deployment on buybacks rather than organic earnings power growth
Customer captivity exists (long-term contracts, deep integrations, strong retention per narrative) but is typical of BPO sector — switching costs are real but not prohibitive for large enterprise clients seeking competitive bids

Red flags

No margin of safety: price ($35.34) is at or above EPV (~$33–35/share), violating the core Greenwald discipline of buying below conservative intrinsic value
78% of DCF value sits in terminal value (valuation block) — the price requires optimistic long-term growth assumptions that EPV methodology specifically refuses to credit
WaveIX AI platform and BPO 3.0 positioning are qualitative claims only — no disclosed client ROI, pricing premium, or quantified competitive advantage appears in any SEC filing reviewed
AI disruption risk is material: over a 5–10 year horizon, AI agents could commoditize Tier 1 contact center work, eroding the labor arbitrage that underpins IBEX's delivery model
Capex spike in FY2025 ($18.4M vs. $8.9M in FY2024, per 10-K filed 2025-09-11) and FY2026 guided to $20–25M (narrative) represents significant growth capex; returns on this capital are unproven and inflate current FCF optically while compressing it in forward periods
Multiple insider sales in May–Jul 2026 (officer, director per narrative) at prices near or below current levels — not a major red flag alone but inconsistent with high insider conviction at current valuation
India expansion (launched Mar 2025, ~1,000 agents per narrative) is early-stage with below-target margins — management is investing in an unproven geography at the same time as the stock trades at full EPV

Howard Marks — 🟡 watch · 55/100 · medium confidence

IBEX presents a modestly interesting risk/return profile from a Marks framework, but it is not yet cheap enough to be a high-conviction contrarian buy, nor is it so dangerous as to warrant avoidance. The DCF intrinsic value of $43.23/share implies roughly 22% upside at $35.34 — a real but thin discount for a business operating in a labor-intensive, commoditizable industry with meaningful structural headwinds from AI. The bar to 'pass' in my framework is a demonstrable margin of safety, ideally with sentiment in the fear-and-revulsion zone; here, sentiment is mixed-to-bullish, the stock recently surged ~15% on a Q3 beat, and management has raised guidance twice. That is not a crisis-priced asset — that is a well-run small-cap with modest momentum. Let me walk through the key dimensions.

PRICE VS. VALUE: The DCF base case at $43.23 uses a 4.24% FCF growth rate (the 3-year revenue CAGR from fundamentals), a 7.89% WACC with a 0.72 beta, and a 2.5% terminal growth rate. These are reasonable but not pessimistic assumptions. The bear-case intrinsic value is $33.67, which is essentially at or below today's price — meaning the margin of safety is thin on a conservative scenario. A true Marks-style discount requires that even the bear case leaves you whole. Here, if growth stalls (plausible given BPO cyclicality) or AI disintermediates a portion of the business, the bear case intrinsic value is within 5% of the current price. That is uncomfortable asymmetry. P/E of 12.84x and price-to-sales of 0.85x are optically cheap for a 16% organic grower, but the BPO industry deserves a discount to the market multiple given low switching costs, margin fragility, and labor-intensity. FCF yield at ~5.8% ($27.3M FCF / $473M market cap) is acceptable but not screaming cheap.

WHAT IS PRICED IN: The consensus narrative — four consecutive quarters of double-digit growth, HealthTech vertical on track to $100M run-rate, AI/WaveIX differentiation, India expansion — is largely already discounted in a stock trading at its recent highs and having just surged 15% post-Q3. The Q2 earnings call (Feb 7, 2026, per narrative) shows guidance raised to $620-630M revenue and $80-82M Adj. EBITDA. The market is not pricing catastrophe; it is pricing continued execution. For a Marks-style contrarian, this is not the moment of maximum pessimism — that was arguably in the $25-26 range (52-week low). The current price embeds at least continued double-digit growth, which is a higher bar to clear.

BALANCE SHEET / MARGIN OF SAFETY IN STRUCTURE: The balance sheet is genuinely clean. Per the 10-Q filed 2026-02-05, total assets are $295.8M, total liabilities $141.3M, and stockholders equity $154.5M. Current ratio is 1.83 (current assets $158.5M vs. current liabilities $86.5M). Cash and equivalents are $15.5M as of December 31, 2025. The debt-to-equity is listed as null in the fundamentals block, suggesting no significant funded debt (consistent with the 10-K showing the TRGI convertible promissory note of $25M was repaid January 9, 2025 per the 10-K filed 2025-09-11). The company is drawing on HSBC Credit Facilities (10-Q references net draws of $19.1M and $7.5M in different periods), but funded debt appears modest. This is a positive — a clean balance sheet means no distress, no covenant risk, no refinancing wall. However, the absence of distress also means the absence of the forced-selling, capital-scarce opportunity that produces the best Marks-style entries.

CYCLE / SENTIMENT POSITIONING: The narrative describes mixed-to-bullish retail sentiment with Elliott Wave traders calling for new highs, options traders positioning for upside, and the stock having already rallied significantly off its $25.94 low. We are not in a fear environment for this name. The BPO sector broadly is in a period of uncertainty (AI disruption fears, offshore wage inflation), but IBEX-specifically is trading with momentum. The insider activity noted in the narrative (officer selling 3,600 shares at $30.61 in June, director selling 1,030 shares in May, CEO withholding on RSU vesting) is small in aggregate but directionally consistent with insiders not aggressively buying at these levels.

AI / DISRUPTION RISK — THE KEY SECOND-LEVEL CONSIDERATION: This is where I find the most material risk that the market may be underpricing. IBEX's WaveIX platform is presented as a differentiator, but the narrative itself acknowledges 'no quantified ROI disclosed for clients, only qualitative commentary.' The BPO industry faces a genuine secular threat: if AI agents can handle tier-1 and tier-2 customer interactions at a fraction of the labor cost, the total addressable market for human-staffed contact centers contracts. IBEX's response — pairing AI with human agents and positioning as 'BPO 3.0' — is the right strategic direction, but it is unproven at scale. The HealthTech and digital-services growth (35% YoY) may reflect a near-term wave of outsourcing demand that could plateau as clients themselves automate. At a 12.84x P/E and 0.85x sales, the market is not fully embedding a disruption scenario, but it is not panic-pricing one either. Over a 3-10 year horizon, the risk that AI meaningfully compresses IBEX's billable-hours base is real and, in my view, not adequately offset by the current margin of safety.

ASYMMETRY ASSESSMENT: Upside — DCF suggests 22% to base ($43.23), 59% to bull ($56.25). Downside — bear case is $33.67 (5% below current price), and a structural AI-disruption scenario could justify values well below that. The risk/reward is not asymmetric in the investor's favor at $35.34; it requires execution of the bull case to generate meaningful returns. This is not 'you can't lose much, but you can win a lot' — it is 'you need to be right on growth AND AI positioning AND margin expansion just to clear the DCF base case.' That is not Oaktree's game.

CONCLUSION: IBEX is a well-run, clean-balance-sheet BPO with real growth momentum and some genuine strategic optionality. But at $35.34, it is priced for continued execution, not priced for fear. The margin of safety is thin (bear DCF = $33.67), sentiment is mixed-to-bullish, the stock has already rallied from the lows, and the secular AI disruption risk is a non-trivial permanent-loss scenario the current price does not adequately compensate for. I rate this a 'watch' — worth tracking for a more compelling entry point, particularly if the stock revisits the low-to-mid $20s on any execution stumble or broader risk-off, at which point the margin of safety would be genuinely attractive.

Key points

DCF intrinsic value of $43.23/share (10-K/fundamentals-sourced inputs) implies 22% upside, but bear-case intrinsic of $33.67 is only 5% below current price — thin margin of safety for a Marks-style position
Balance sheet is structurally clean: stockholders equity $154.5M vs. total liabilities $141.3M, current ratio 1.83, TRGI convertible note ($25M) repaid January 9, 2025 per 10-K filed 2025-09-11; no covenant or refinancing risk
FCF yield ~5.8% ($27.3M / $473M market cap) and P/E of 12.84x are optically cheap but not crisis-priced for a labor-intensive BPO with secular disruption risk
Sentiment is mixed-to-bullish (stock surged ~15% post-Q3 per narrative, Elliott Wave traders calling for new highs); this is not a fear-and-revulsion entry point; the $25.94 low was the Marks-style opportunity
Operating momentum is real: four consecutive quarters of double-digit organic growth, guidance raised to $620-630M revenue (Q2 FY2026 earnings call per narrative), HealthTech vertical targeting $100M run-rate — but this is now the consensus view, already partially priced
Share repurchase activity is capital-return positive: $20M new program authorized May 2026 (8-K filed 2026-05-13); $10.1M repurchased in 9 months ended March 31, 2026 (10-Q filed 2026-05-06); reduces share count but funded from thin cash balance
Insider selling pattern (officer 3,600 shares at $30.61, director 1,030 shares, per narrative) is directionally neutral-to-negative; insiders not aggressively buying at $35

Red flags

Bear-case DCF ($33.67) is within 5% of current market price — essentially no downside protection if growth stalls; a structural AI disruption scenario could justify values well below the bear case
AI/WaveIX claims are qualitative with no quantified client ROI per narrative; BPO faces genuine secular headwind if AI agents commoditize tier-1/2 contact center work over a 3-10 year horizon — this is an unpriced or underpriced permanent-impairment scenario
Sentiment is not in fear territory: stock rallied ~15% post-Q3 beat, guidance raised twice, retail commentary includes 'new highs' calls; buying into momentum is the opposite of Marks-style contrarian discipline
Elevated near-term capex (10-Q filed 2026-05-06 shows $24.6M capex in 9 months ended March 31, 2026 vs. $13.2M prior year) compressing near-term FCF; 9-month FCF of $9.5M vs. $4.5M prior year but capex trajectory is rising with India/offshore expansion
Customer concentration and contract risk not fully disclosable from available filings: single client at 10% of revenue, top 25 at 79%; loss of one or two anchor clients would materially impair the DCF
Offshore labor arbitrage advantage may erode as wage inflation spreads in Philippines, Pakistan, Nicaragua, Jamaica — margin expansion thesis depends partly on sustained wage differentials that are structurally narrowing

Michael Mauboussin — 🟡 watch · 55/100 · medium confidence

IBEX Ltd is a BPO/CX outsourcing company with a modestly attractive ROIC/WACC spread, but the moat is narrow and structurally contested by AI disruption. Working backwards from the current price of $35.34, the DCF base case implies ~22% upside to intrinsic value of $43.23, using 4.24% FCF growth and a 7.89% WACC — modest embedded expectations that are plausibly achievable but leave limited margin of safety given the moat's fragility. ROIC is reported at 23.8% and ROE at 23.9% (fundamentals block), which is a meaningful spread above the 7.89% WACC. But this ROIC deserves scrutiny: (1) IBEX is an asset-light labor-services business with offshore delivery, so high ROIC is partly a function of low invested capital denominator, not a defended franchise extracting pricing power; (2) FCF margins are thin at 4.89% (FY2025, 10-K filed 2025-09-11), barely budging from 4.38% in 2023 and actually declining from the FY2024 level of 5.32%; and (3) operating margins at 8.35% are in the narrow band typical of contract BPO operators globally, with no evident pricing power to expand them structurally. The moat assessment is the crux. On switching costs: enterprise BPO contracts carry meaningful procedural and relational switching costs — client data integration, trained agent pools, embedded CX workflows — giving IBEX a Narrow moat that is real but not wide. On scale economies: IBEX's offshore delivery in Philippines, Pakistan, Nicaragua, and Jamaica (noted in 10-Q filed 2026-05-06 and 10-K filed 2025-09-11) provides labor cost arbitrage but not proprietary scale economics that structurally decline per-unit cost as volume grows — peers can replicate this by adding headcount in the same geographies. On network effects: none identified. On intangibles: the WaveIX AI platform is mentioned prominently in management commentary (Q2 FY2026 earnings call), but no quantified client ROI, no disclosed proprietary data assets, no patent portfolio mentioned in any SEC filing. Treating this as a meaningful intangible moat at this stage would be speculative. Moat verdict: Narrow, trajectory ambiguous — potentially eroding if AI automates tier-1 contact center work faster than IBEX can reposition. Reading embedded expectations: at $35.34, P/E = 12.84x (FY2025 net income $36.9M), P/FCF = 17.34x, P/S = 0.85x. For a company growing revenue 16–17% YoY (per earnings call Q2 FY2026) with double-digit EPS growth, these multiples are not demanding — the market is embedding something closer to mid-single-digit normalized growth and flat-to-declining margins, consistent with base-rate BPO sector mean reversion. This creates a potentially attractive setup IF the current growth trajectory is durable, but the outside-view base rate for BPO companies sustaining 15%+ revenue growth for more than 2–3 years is low; the sector average is 5–8% per the narrative. The probability distribution I assign: bull case (~25% weight, $50–56 implied) requires sustained double-digit growth via HealthTech/AI differentiation and India expansion materializing; base case (~50% weight, $38–43) requires current momentum continuing at a decelerating pace with modest margin expansion; bear case (~25% weight, $28–34) reflects AI-driven commoditization of tier-1 CX, telecom client atrophy accelerating, and India expansion costs exceeding returns. The fat tail risk is AI disruption — specifically, if large language model-powered voice/chat agents automate 30–50% of tier-1 contact center volume over a 3–7 year horizon (a plausible scenario given the pace of LLM deployment), IBEX's revenue base contracts materially. The company's WaveIX positioning is a hedge but also an acknowledgment of the threat. Unlike platform businesses with network effects or proprietary data moats, IBEX cannot easily turn AI into a switching-cost amplifier — if AI commoditizes CX delivery, the labor arbitrage advantage evaporates. Management capital allocation discipline is mixed: the TRGI share repurchase ($70M for 3.56M shares at roughly $19.65/share per 10-K filed 2025-09-11) was at attractive valuations; the new $20M buyback authorized May 2026 (8-K filed 2026-05-13) at prices in the $30s is more questionable given the bear-case risk. Operating cash flow is real ($45.7M in FY2025 per 10-K), capex is accelerating ($18.4M in FY2025 vs. $8.9M prior year), and H1 FY2026 shows elevated capex ($19.4M in first 6 months per 10-Q filed 2026-02-05) — free cash flow is being consumed by offshore expansion, creating near-term FCF compression. Evidence that would revise my view upward: disclosed client-level pricing premiums tied to AI; sustained gross margin expansion (not just operating leverage from SG&A); India reaching scale with disclosed margin profile; evidence that LLM automation is complementing rather than displacing IBEX agents. Evidence that would revise downward: further FCF margin compression, large client concentration risk crystallizing, or AI pilot programs showing displacement rather than augmentation.

Key points

ROIC of 23.8% materially exceeds WACC of 7.89%, creating a positive spread — but this is partly a low-capital-base artifact of an asset-light offshore labor model, not a defended pricing-power franchise (fundamentals block)
Moat is Narrow via switching costs (embedded CX workflows, trained agent pools, multi-year enterprise contracts) but lacks network effects, scale economics, or verifiable intangible IP — trajectory is ambiguous to eroding under AI pressure
Embedded expectations at 12.84x P/E and 0.85x P/S are modest and consistent with base-rate BPO mean-reversion assumptions, creating a potentially attractive setup if growth proves more durable than the outside view suggests
HealthTech vertical growing 35.1% YoY and expected to hit $100M run rate (per Q2 FY2026 earnings call) — if this vertical achieves dominant positioning with healthcare-specific switching costs, it could narrow the moat's trajectory question materially
FCF margin actually declined from 5.32% (FY2024) to 4.89% (FY2025) despite revenue growth, reflecting capex acceleration for offshore expansion — near-term FCF compression is a headwind to the DCF's assumed stable growth rate
Share count reduction from 16.5M to 14.7M weighted diluted shares YoY (per earnings call) shows disciplined buyback execution at attractive valuations; the TRGI repurchase at ~$19.65/share was well below intrinsic value
Revenue CAGR of 4.24% (3-year, fundamentals block) is the DCF's growth proxy but understates the current momentum (16–17% YoY per Q2 FY2026) — creates forecast uncertainty in both directions

Red flags

AI disruption risk is material and structural: if LLM-powered agents automate tier-1 contact center volume over 3–7 years, IBEX's labor arbitrage model faces secular revenue pressure — WaveIX claims are qualitative with no quantified client ROI in any SEC filing
FCF margin is thin (4.89%) and declining, with H1 FY2026 free cash flow of only $2.9M on $24.6M capex (10-Q filed 2026-02-05) — capex acceleration could persist longer than management implies, compressing the DCF's base FCF assumption
BPO sector outside-view base rate for sustaining 15%+ revenue growth beyond 2–3 years is low (~5–8% sector average per narrative); the current multiple, though modest, requires growth durability that is historically rare for the sector
Telecom vertical declining 23.1% YoY (per Q2 FY2026 earnings call) and now below 10% of revenue for the first time — while diversification is improving, continued attrition from this legacy base could create a revenue air pocket if HealthTech/Travel growth decelerates
Insider selling pattern (officer sold 3,600 shares at $30.61 in Jun 2026, director sold 1,030 shares in May 2026, per narrative) — small in aggregate but directionally consistent with insiders not treating the stock as deeply discounted at current prices
WaveIX AI platform positioning is strategically necessary but unverifiable as a moat source — no patent disclosures, no proprietary data asset described in any SEC filing, and larger competitors (Accenture, Atos, TTEC) have equivalent or greater AI investment capacity

Chuck Akre — 🟡 watch · 52/100 · medium confidence

IBEX presents a genuinely mixed picture through the Akre three-legged stool. Leg one (extraordinary business): IBEX is a BPO/contact center operator — an inherently labor-intensive, low-margin, commoditized service business. Operating margin of 8.4% and FCF margin of ~4.9% (10-K filed 2025-09-11) are not the hallmarks of a franchise business with pricing power. These are thin margins that leave little buffer and suggest the business competes largely on price and geography rather than a durable moat. However, IBEX is evolving — offshore mix is rising, HealthTech is growing 35%+ YoY and on track for $100M run rate, and the WaveIX AI platform is claimed as a differentiator. Leg two (management skill and integrity): The TRGI Purchase Agreement (10-K 2025-09-11) — in which IBEX purchased 3,562,341 shares from its controlling shareholder TRGI for $70M ($45M cash + $25M convertible note repaid Jan 2025) — is a material related-party transaction that warrants scrutiny. While the note was repaid quickly, paying $70M to a related party to buy back shares is a significant capital allocation decision that could represent either excellent or self-serving management depending on the price paid relative to intrinsic value. The $1.1M impairment on non-current related-party assets (10-K 2025-09-11) adds a modest integrity caution. Multiple insider sales (director, officer, CEO RSU withholding per narrative) in May–Jul 2026 at prices near current levels are mildly concerning. On the positive side, the $15M and $20M buyback authorizations (8-K filings 2026-05-13 and 10-Q 2026-05-06) at prices well below the DCF intrinsic value of $43.23 appear rational capital allocation. CEO Robert Dechant appears operationally focused. Leg three (reinvestment runway): This is the most interesting leg. HealthTech vertical growing rapidly from zero in 2021, India expansion launched March 2025, offshore mix shift — these represent genuine reinvestment opportunities. However, the reinvestment is into labor arbitrage and geographic expansion, not into proprietary intellectual capital. ROIC of 23.8% and ROE of 23.9% (fundamentals data) are impressive figures IF sustainable without leverage — and importantly, debt-to-equity appears low (total liabilities $141M vs equity $154M per 10-Q 2026-02-05 period 2025-12-31), which is reassuring. Returns are not obviously leverage-driven. However, the ROE/ROIC figures need validation: the TRGI buyback reduced share count dramatically (from ~16.5M diluted to ~14.7M per narrative, and 13.3M shares outstanding per fundamentals), which mechanically inflates per-share metrics. Revenue CAGR of only 4.2% over three years does not suggest a compounding machine. FCF of $27.3M on $558M revenue (4.9% FCF margin) is thin. The DCF base intrinsic value of $43.23 vs current price $35.34 implies 22% upside — a modest margin of safety but not a screaming discount for a business with these economics. The P/E of 12.8x and price-to-sales of 0.85x are undemanding, supporting the 'watch' rather than 'avoid' conclusion. AI risk is a two-edged sword: IBEX is actively positioning WaveIX as an enabler, claiming first-mover advantage in AI-augmented CX, but the existential risk is real — AI agents could over a 5-10 year horizon displace significant volumes of contact center work, commoditizing the very service IBEX provides. No client pricing premiums for AI have been quantified in filings or transcripts. The business is not a classic Akre compounder — too labor-intensive, too thin on margins, insufficient evidence of a durable moat — but the valuation is undemanding, returns are respectable, and the growth vectors (HealthTech, India, AI positioning) provide a plausible reinvestment story. Score of 52 reflects two-of-three legs partially present.

Key points

ROE 23.9% and ROIC 23.8% are above Akre's 20%+ threshold and appear achieved without meaningful financial leverage (total liabilities $141M vs equity $154M per 10-Q period 2025-12-31) — this is the strongest Akre-positive signal
DCF intrinsic value $43.23 vs current price $35.34 offers ~22% upside margin of safety; P/E 12.8x and price-to-sales 0.85x are undemanding for a growing services business
Genuine reinvestment runway exists: HealthTech growing 35%+ YoY from zero in 2021, India expansion (two sites, ~1,000 agents, launched March 2025), offshore mix rising — capital being redeployed into higher-return geographies
Share buybacks at $10.1M (nine months ended March 31, 2026 per 10-Q 2026-05-06) executed well below DCF intrinsic value; rational capital allocation signal; share count declining materially from ~16.5M to ~13.3M
Four consecutive quarters of double-digit organic revenue growth; FY2026 guidance raised to $620-630M; management credibility building on beat-and-raise track record

Red flags

BPO is inherently labor-intensive and low-margin (FCF margin 4.9%, operating margin 8.4% per 10-K 2025-09-11) — not the capital-light, high-margin franchise with pricing power that Akre seeks as leg one
TRGI Purchase Agreement: $70M paid to controlling related party for share repurchase (10-K 2025-09-11) is a significant related-party transaction; $1.1M impairment on related-party non-current assets in same year adds integrity caution — fact base does not allow full assessment of whether price was fair
AI existential risk: contact center volumes could be materially displaced by AI agents over 5-10 year horizon; WaveIX AI claims are qualitative and unverified in filings — no quantified client ROI or pricing premium evidence in the fact base
Revenue CAGR of only 4.2% over three years (fundamentals) is below what Akre would expect from a true compounder; thin FCF margin means modest earnings power relative to revenue scale
Multiple insider sales in May-Jul 2026 (officer sold 3,600 shares at $30.61 per narrative, director sold 1,030 shares) at prices near or below current levels; while individually small, the pattern warrants monitoring for management conviction signals

Warren Buffett — 🟡 watch · 52/100 · medium confidence

IBEX is an understandable business — a BPO/contact center operator generating real revenue and profits — so it sits within a circle of competence. However, it fails several Buffett criteria that matter most: the moat is thin and unproven, the margins are narrow, and the capital economics are only marginally attractive. Let me be specific. On the positive side: ROE of 23.9% and ROIC of 23.8% (per fundamentals block) are impressive numbers, and net income has grown consistently from $13M (FY2021) to $37M (FY2025) per the historical table. The business is cash-flow positive, carries modest debt (debt-to-equity not explicitly stated but total liabilities of $141M vs. equity of $155M suggest manageable leverage per the 10-Q filed 2026-02-05), and management is actively buying back shares — $15M authorized in May 2025 and a new $20M program in May 2026 (per the 8-K filed 2026-05-13). The buybacks appear to be at prices below the DCF intrinsic value of $43.23, which is rational capital allocation. Price-to-sales of 0.85x and P/E of 12.84x look inexpensive on the surface. However, the core Buffett concern is the moat. BPO/contact center services are largely commoditized: clients can and do shift volumes between providers based on price and labor arbitrage. There is no evidence in the filings of durable pricing power — operating margins are only 8.35% and FCF margins are ~4.9% (FY2025, per fundamentals). These are thin margins for a 'wide moat' business. A Coca-Cola or See's Candies this is not. The WaveIX AI platform claim is qualitative commentary from a single earnings call (Feb 7, 2026 per the narrative) with no quantified client ROI disclosed — I cannot verify this as a real moat. Capex has been rising (from $8.9M in FY2024 to $18.4M in FY2025, per the 10-K filed 2025-09-11, and $24.6M in the nine months ended March 2026 per the 10-Q filed 2026-05-06), suggesting the business requires ongoing reinvestment simply to maintain and expand capacity. Owner earnings after maintenance capex are harder to isolate, but if growth capex is substantial, true maintenance FCF may be meaningfully below the reported $27M. Revenue CAGR of only 4.2% over three years (per fundamentals) before the recent acceleration is modest. The telecom vertical decline (noted in narrative as now below 10% of revenue, down from 13.1%) shows vulnerability to client mix shifts. India expansion (launched March 2025 per narrative) adds execution risk without a proven track record. Multiple insider sales in May-July 2026 (director, officer, CEO RSU withholding per narrative) are a mild negative signal, though not alarming individually. The DCF shows 22% upside to $43.23 intrinsic per share from $35.34, which offers some margin of safety, but not the fat pitch — 50 cents on the dollar — that I prefer. AI disruption is a genuine two-sided risk: on one hand, IBEX's AI positioning (WaveIX) could help it win clients and defend margins; on the other, AI-driven automation of contact center work is precisely the kind of technological disruption that could erode the core labor-arbitrage model over a 5-10 year horizon. If AI agents replace human agents at scale, IBEX's entire revenue model faces structural pressure. I cannot assess WaveIX as a genuine competitive hedge without evidence of monetization. In sum: a decent business at a cheap price, but not a wonderful business at a fair price. Watch rather than avoid because the economics are real and improving, but I would not deploy significant capital without clearer moat evidence.

Key points

ROE of 23.9% and ROIC of 23.8% are strong numbers, achieved with modest leverage (total liabilities ~$141M vs. equity ~$155M per 10-Q filed 2026-02-05)
Net income has grown consistently from $13M (FY2021) to $37M (FY2025) per the historical fundamentals table — a real, proven earnings record over five years
Rational share repurchases: $15M program (May 2025) and new $20M program (May 2026, per 8-K filed 2026-05-13) executed at prices below DCF intrinsic value of $43.23
P/E of 12.84x and price-to-sales of 0.85x represent undemanding valuations; DCF offers ~22% upside suggesting modest margin of safety
Revenue concentration is reasonable: top client 10%, top 10 at 39%, top 25 at 79% (per narrative from Feb 2026 earnings call) — no dangerous single-client dependency
HealthTech vertical growing 35% YoY and approaching $100M run rate (per narrative) shows diversification away from declining telecom

Red flags

Operating margin of only 8.35% and FCF margin of ~4.9% (FY2025, fundamentals) are thin for a moat-endowed business — these are commodity-level margins
Capex is rising rapidly: $8.9M in FY2024 to $18.4M in FY2025 (10-K filed 2025-09-11) to $24.6M in nine months ending March 2026 (10-Q filed 2026-05-06) — the business is capital-hungry, not capital-light
BPO/contact center industry has no durable pricing power: labor arbitrage is replicable and competition is intense; no evidence of switching costs or brand moat in the filings
WaveIX AI 'moat' claim is unverified marketing commentary from a single earnings call with zero quantified client ROI — cannot be counted as an economic moat
AI disruption risk is structural and severe: if AI agents automate contact center work, IBEX's labor-arbitrage model faces existential pressure over a 5-10 year horizon
Multiple insider sales in May-July 2026 (director, officer, CEO RSU withholding) noted in the narrative — not alarming individually but directionally negative
Revenue CAGR of only 4.2% over three years (fundamentals) before recent acceleration raises questions about whether current growth rates are sustainable or cyclical

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

IBEX presents a genuinely interesting earnings inflection story — four consecutive quarters of double-digit organic growth, a guidance raise pattern (raised twice in FY2026), accelerating HealthTech vertical (+35% YoY, approaching $100M run rate), and meaningful share count reduction (~10% YoY from buybacks including the large TRGI block purchase). The forward earnings direction is clearly up: FY2026 guidance of $620–630M revenue implies ~12% growth over FY2025's $558M, with EBITDA guidance of $80–82M. The second derivative on earnings is positive — net income has gone from $13M (FY2021) to $37M (FY2025) and EPS is accelerating faster than revenue due to buybacks (diluted shares down materially per the Q2 earnings commentary showing 14.7M vs 16.5M YoY). These are the ingredients I look for. However, several things stop me from sizing this as a high-conviction concentrated position. First, liquidity is a real problem — market cap is ~$473M with a tiny float (~13.3M shares outstanding per fundamentals block), thin volume for a concentrated macro bet; I cannot enter and exit fast enough if the thesis breaks, which violates one of my core operating rules. Second, the tape is constructive but not decisively bullish — the stock is 17.8% below its 52-week high of $42.99 and was in the mid-$30s after a Q3 earnings surge; it has not made new highs or shown the kind of sustained relative strength that confirms a true leadership breakout. Third, the macro/liquidity regime context is absent from this fact base — I cannot assess whether the Fed cycle is a tailwind or headwind here, which is central to my framework; without knowing the prevailing liquidity environment, I cannot make a high-conviction directional bet. Fourth, AI disruption risk is real and two-sided: IBEX's BPO model is directly in the crosshairs of AI automation (voice agents, LLM-based customer service) over a 3–7 year horizon. Their WaveIX positioning is claimed but unquantified in the filings — no disclosed revenue from AI, no client ROI data, no pricing premium evidence. The risk is that AI commoditizes exactly what IBEX sells, and larger players (Accenture, Teleperformance) have deeper AI budgets. Fifth, the FCF picture in the current fiscal year (9 months ending March 2026) shows only $9.5M free cash flow vs $4.5M prior year — capex is running at $24.6M for 9 months vs $13.2M prior year (10-Q filed 2026-05-06), meaning the India expansion and offshore build-out are consuming cash aggressively. The DCF intrinsic value of $43.23 (22% upside) with a bear case of $33.67 defines the risk/reward as roughly 2:1, acceptable but not the 5:1 asymmetry I want for a concentrated bet. The TRGI share purchase ($70M at ~$19/share equivalent, financed partly with a convertible note repaid Jan 2025 per the 10-K filed 2025-09-11) was smart capital allocation that massively reduced share count, but it is a one-time event. Multiple insider sales in May–July 2026 at $30–31 levels (per narrative) are not alarming in isolation but are worth noting as insiders trimming into the rally. Net: the fundamental direction is right, the earnings inflection is real, but the liquidity/size constraints, unconfirmed tape leadership, absent macro context, and AI overhang prevent a high-conviction 'pass' verdict. This belongs on the watch list pending a new-highs breakout, clearer Fed tailwind evidence, and evidence that WaveIX is generating measurable pricing power.

Key points

Four consecutive quarters of double-digit organic growth; FY2026 guidance raised twice to $620–630M revenue / $80–82M EBITDA (narrative, Q2 FY2026 earnings call)
EPS accelerating sharply — Q2 FY2026 adjusted EPS +46% YoY; diluted share count down ~10% YoY (14.7M vs 16.5M) via aggressive buybacks including $70M TRGI block (10-K 2025-09-11)
HealthTech vertical +35% YoY, approaching $100M run rate from a 2021 launch — genuine secular vertical winner within BPO mix
Net income trajectory strongly up: $13M (FY2021) → $37M (FY2025) per fundamentals history; margins expanding (EBITDA margin 12.9% FY2025 per 10-K 2025-09-11)
Share count reduction is durable: new $20M buyback authorized May 2026 (8-K 2026-05-13) on top of $15M program with $3.2M remaining (10-Q 2026-05-06)
DCF intrinsic value $43.23 vs $35.34 current price = 22% upside; bear case $33.67 provides modest but defined floor

Red flags

Market cap ~$473M, ~13.3M shares outstanding — float is too thin for meaningful concentrated position sizing; cannot enter/exit at Druckenmiller-scale without moving the market
Stock is 17.8% below 52-week high ($42.99); no confirmed new-highs breakout or sustained relative strength leadership — tape has not yet validated the fundamental inflection
Capex running $24.6M for 9 months of FY2026 vs $13.2M prior year period (10-Q 2026-05-06), compressing FCF to only $9.5M YTD — investment cycle absorbing cash, FCF visibility clouded
AI disruption risk is material and unquantified: WaveIX claims are qualitative only; no disclosed revenue from AI services, no pricing premium data in any filing; BPO voice/chat work is primary target of LLM automation over 3–7 year horizon
Macro/liquidity regime context absent from fact base — cannot assess Fed cycle direction, which is the primary variable in my framework
Insider selling pattern in May–July 2026 at $30–31 (officer, director per narrative) — not alarming but insiders not buying into the AI/growth story with new capital
Telecom vertical (legacy) declining 23% YoY and still material; if macro weakens, HealthTech/Retail clients may also cut BPO spend, creating downside surprise risk

Philip Fisher — 🟡 watch · 52/100 · medium confidence

IBEX is a BPO/contact-center operator that is demonstrating genuine above-industry organic revenue growth (16–17% YoY in recent quarters vs. BPO peer average of ~5–8% per the narrative), an accelerating vertical mix shift toward HealthTech and digital services, and early-stage AI positioning via its WaveIX platform. However, by Fisher's criteria the story is incomplete and carries structural concerns. The company lacks meaningful R&D spend (no R&D line disclosed anywhere in the fact base — this is a services business, not a product innovator), which is a central pillar of my framework. Growth is real but the organic drivers are primarily labor arbitrage, offshore mix shift, and vertical wins rather than proprietary product pipelines that compound durably. Management appears candid (guidance raised twice, headwinds acknowledged including India margin drag and deferred training revenue), and the new Chief AI & Digital Officer appointment signals long-term orientation. But AI positioning is qualitative and unverified — no quantified client ROI, no disclosed R&D budget, no concrete evidence that WaveIX creates a defensible moat rather than a marketing narrative. Margins are thin (operating margin 8.35%, net margin 6.6% per fundamentals) and FCF margin only ~4.9%. Insider selling in May–July 2026 (officer, director) is a mild negative signal. The DCF base-case implies ~22% upside to $43.23, which is not a Fisher-style multi-year compounder; the terminal value represents 78% of enterprise value, meaning the DCF is heavily dependent on assumptions about a business with inherently thin margins and high labor cost exposure. On AI disruption specifically: BPO/contact center is arguably the sector most directly in the crosshairs of AI automation over a 3–10 year horizon. Management's 'BPO 3.0' framing is the right strategic response, but IBEX is a small player ($473M market cap) deploying AI tools built largely on third-party infrastructure; the risk that AI commoditizes or outright disintermediates large swaths of the business (tier-1 client support, tier-1 voice work) is material and not adequately offset by the current WaveIX narrative. A Fisher holding requires a franchise that compounds organically for a decade or more; I cannot see that here with confidence.

Key points

Revenue CAGR of 4.24% over 3 years (fundamentals) but recent organic acceleration to 16.7% YoY in Q2 FY2026 is impressive and well above BPO industry average of 5–8% (narrative, Q2 FY2026 earnings call)
HealthTech vertical grew 35.1% YoY and is on track for $100M run rate from a 2021 launch — this is genuine new-market development consistent with Fisher Point 1 (narrative)
WaveIX AI platform and 'BPO 3.0' framing suggest management has a long-range strategic vision, though entirely unverified by financial metrics (narrative)
India market entry (March 2025, two sites, ~1,000 agents) represents a genuine new geographic growth vector identified as 'one of our highest growth vectors' — consistent with Fisher's criterion of management planning beyond current product lines (narrative, 10-K FY2025 and 10-Q filed 2026-05-06)
Share count reduction ~10% YoY via buybacks signals capital discipline and long-term orientation rather than dilutive growth financing (10-Q filed 2026-05-06, 8-K filed 2026-05-13 authorizing additional $20M)
SG&A declining as percentage of revenue (18.3% to 16.8%) demonstrates operating leverage and cost discipline (narrative)
Management has raised full-year guidance twice and explicitly acknowledged temporary headwinds (India ramp, deferred training revenue) — consistent with candor Fisher prizes (narrative)
Single operating segment reporting with consolidated CODM view is clean; no evidence of accounting complexity or aggressive estimates changes (10-K filed 2025-09-11, 10-Q filed 2026-05-06)

Red flags

No R&D line item disclosed anywhere in the fact base — this is a fundamental gap for a Fisher assessment; BPO services companies do not invest in proprietary products in the traditional sense, undermining the core of my framework
WaveIX AI platform claims are entirely qualitative with zero quantified client ROI, no disclosed technology investment budget, and no independent corroboration — promotional risk (narrative, bear section)
FCF margin only 4.9% (FY2025, fundamentals) with CapEx rising ($18.4M in FY2025 vs $8.9M in FY2024 per 10-K filed 2025-09-11); near-term FCF actually negative in H1 FY2026 ($(5.1)M in Q2, per 10-Q filed 2026-02-05)
AI automation is an existential risk to the core BPO/contact-center business model over 3–10 years; a company with 8.35% operating margins has limited buffer to absorb structural volume declines from AI substitution
Multiple insider sales May–July 2026 (officer sold 3,600 shares at $30.61 June 16, director sold 1,030 shares May 29 per narrative) — not alarming in isolation but directionally inconsistent with strong insider conviction
Telecom vertical (legacy, high-margin historically) declining 23.1% YoY and now below 10% of revenue — this is involuntary mix shift, not strategic repositioning (narrative)
India operations still below expected margins with no timeline disclosed for reaching target profitability — execution risk on the highest-growth vector (narrative)
The business is fundamentally labor-intensive with delivery in Philippines, Pakistan, Nicaragua, Jamaica (10-Q filed 2026-05-06); labor arbitrage is not a durable moat by Fisher standards — it can be competed away or disrupted by automation

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

IBEX Ltd presents a mixed picture against classic Graham criteria. On the positive side, the company has demonstrated consecutive years of profitability since at least 2021 (per the history block), is trading at a P/E of 12.84x which sits modestly below Graham's defensive cap of 15x, and the DCF intrinsic value of $43.23 per share implies a 22% upside to the current $35.34 price — a margin of safety, but not the one-third discount Graham demanded. The earnings yield of ~10.2% (fundamentals block) materially exceeds typical high-grade bond yields, which is favorable. The revenue CAGR of 4.2% over three years is modest but positive. However, several Graham criteria are either not met or are borderline. The current ratio is 1.83 (fundamentals block), falling short of Graham's preferred 2.0 floor. Debt-to-equity is listed as null in the fact base, leaving long-term debt versus working capital comparison incomplete — a genuine data gap. P/B stands at 3.06x (fundamentals block), and with P/E at 12.84x, the P/E x P/B composite is approximately 39.3, far above Graham's 22.5 ceiling. Net current asset value (NCAV) is current assets $158.5M minus total liabilities $141.3M = ~$17.2M, or roughly $1.29 per share, far below the $35.34 market price — so no net-net opportunity exists. The company pays no disclosed dividend (no mention in any filing or narrative), which fails Graham's dividend reliability criterion. Free cash flow margins are thin (4.9% in FY2025, per 10-K filed 2025-09-11), and the FCF was actually negative in early FY2026 quarters due to elevated capex (10-Q filed 2026-02-05 shows FCF of –$5.1M in Q2 and –$5.1M in the three months ended December 31, 2025). The TRGI share repurchase of $70 million (10-K filed 2025-09-11) — $45M cash plus $25M convertible note, repaid January 2025 — was a large capital deployment that temporarily strained the balance sheet. The balance sheet data is as of December 31, 2025 (10-Q period), while income statement data runs to June 30, 2025 fiscal year-end, creating a timing mismatch that limits precision. On AI disruption: as a pure BPO operator, IBEX faces genuine medium-term risk that AI automation displaces the labor-intensive contact center work that constitutes its entire revenue base. Management's WaveIX positioning is qualitative and unquantified (narrative); I cannot confirm from filings that this creates a durable protective moat. Graham would be skeptical of story-driven AI narratives and would demand demonstrated earnings protection. The stock is not wildly expensive, but it does not offer the conservative margin of safety, balance-sheet fortress, or dividend track record that Graham's framework requires for a confident 'pass.' It is a 'watch' — monitoring for price weakness toward a more compelling discount, ideally below $30, which would widen the margin of safety toward or beyond one-third.

Key points

P/E of 12.84x (fundamentals block) is modestly below Graham's 15x defensive ceiling; earnings yield ~10.2% exceeds high-grade bond yields — a genuine positive.
DCF intrinsic value $43.23 vs. price $35.34 implies ~22% upside (valuation block), but falls short of Graham's preferred one-third margin of safety.
Positive earnings every year from 2021 through 2025 (history block) satisfies the earnings stability criterion over the available look-back window.
NCAV calculation (current assets $158.5M minus total liabilities $141.3M = ~$17.2M, per 10-Q filed 2026-02-05) yields ~$1.29/share — far below market price; no net-net possibility.
Revenue CAGR 4.2% over 3 years (fundamentals block) is modest, consistent with slow-but-steady growth Graham tolerates.

Red flags

P/E x P/B composite (~39.3) far exceeds Graham's 22.5 ceiling (P/E 12.84 x P/B 3.06, from fundamentals block).
Current ratio 1.83 (fundamentals block) falls below Graham's preferred 2.0 floor; balance sheet not a fortress.
No dividend disclosed in any filing or narrative — fails Graham's dividend reliability criterion entirely.
Debt-to-equity listed as null in the fact base; long-term debt vs. working capital comparison cannot be completed — a material data gap.
FCF turned negative in early FY2026 quarters (three months ended December 31, 2025: –$5.1M per 10-Q filed 2026-02-05), suggesting earnings quality is lumpy and capex-sensitive.
AI disruption risk is material and unquantified: BPO labor-intensive model is precisely the type AI could commoditize over a 3-10 year horizon; management's WaveIX claims are qualitative only (narrative) with no filing-level financial quantification.

Seth Klarman — 🟡 watch · 52/100 · medium confidence

IBEX presents a mildly interesting value situation but falls meaningfully short of the margin-of-safety bar I require before deploying capital. The DCF intrinsic value of $43.23 per share versus a $35.34 market price implies roughly 22% upside — a real but modest discount that barely clears a conservative floor, especially when I stress-test the assumptions. The DCF leans heavily on terminal value (78% of enterprise value per the fact base), which means the equity story depends almost entirely on sustained long-run growth, not on asset coverage or near-term cash realization. That is exactly the structure I distrust. On the asset side: total assets of $295.8M against liabilities of $141.3M yields book equity of $154.5M, implying a price-to-book of ~3.1x (per fundamentals). There is no meaningful tangible asset coverage — the balance sheet is dominated by intangibles, right-of-use assets, and human-capital-intensive goodwill in a services business. A liquidation scenario would yield well below book, providing no real downside floor. On normalized cash flow: FCF of $27.3M on a market cap of ~$473M gives a price-to-FCF of ~17x. That is not cheap for a BPO operator with thin FCF margins (~4.9%) operating in a commoditizing labor-arbitrage industry. However, the P/E of ~12.8x and price-to-sales of 0.85x are genuinely modest multiples for a business generating 23.9% ROE and 23.8% ROIC (per fundamentals). Net cash of ~$15.5M on the balance sheet is minimal relative to the enterprise, providing limited cushion. Capital allocation is mixed: the company completed a $70M share repurchase from TRGI (November 2024, per the 10-K), paid $45M cash plus a $25M convertible note (repaid January 2025), and has authorized an additional $20M buyback (May 2026 8-K). The pace of buybacks is encouraging but the TRGI transaction significantly depleted cash, and the balance sheet is now lean. The business itself is operationally sound — four consecutive quarters of double-digit organic growth, margin stability at ~12.9% adjusted EBITDA (10-K, FY2025), improving mix toward higher-margin offshore and HealthTech verticals — but operational excellence is not the same as a value opportunity. AI risk is the central structural threat I cannot dismiss: IBEX's WaveIX positioning and BPO 3.0 narrative are qualitative claims without disclosed client ROI metrics. The risk that AI automation — deployed either by clients themselves or by larger competitors — commoditizes or displaces labor-arbitrage BPO volume is real and 3-to-7-year in nature. IBEX's moat rests on skilled human agents, offshore cost arbitrage, and client relationships, all of which could be eroded by AI-driven automation. Management is lean on hard evidence that WaveIX protects pricing; it may instead accelerate the commoditization they are trying to avoid. The situation lacks the catalysts I prefer: no spin-off, no distressed dynamic, no forced seller (the TRGI block trade was the closest analog but has already closed), no litigation windfall, no index-deletion mispricing. This is a modestly undervalued, operationally healthy BPO operator — not a mispriced, orphaned, or catalyst-rich special situation. At ~22% upside to DCF with 78% terminal-value dependency and no hard asset floor, the margin of safety is insufficient to justify a full position. I would watch for a price closer to $25–28 (where the discount to conservative going-concern value becomes more compelling and the downside is better absorbed) or for a specific catalyst that closes the gap faster.

Key points

DCF intrinsic value of $43.23 implies ~22% upside, but 78% of enterprise value resides in terminal value — the thesis depends on long-duration growth assumptions that cannot be stress-tested with confidence (valuation block)
Price-to-sales of 0.85x and P/E of 12.8x are genuinely modest multiples; ROIC of 23.8% and ROE of 23.9% signal a returns-productive business (fundamentals block)
FCF of $27.3M on $473M market cap yields ~17x price-to-FCF — not a bargain price for a thin-margin (~4.9% FCF margin) labor-intensive services business (10-K FY2025, fundamentals)
Share buyback discipline is positive: $70M TRGI block repurchase (Nov 2024, 10-K) plus ongoing $15M and $20M programs (10-Q March 2026, 8-K May 2026) reducing share count materially (~10% YoY per narrative)
Net cash of $15.5M (fundamentals) is minimal; balance sheet provides no meaningful downside cushion after TRGI transaction drained liquidity
HealthTech vertical growing 35% YoY and India expansion underway (narrative) are genuine growth vectors but are growth-dependent, not asset-backed, value drivers

Red flags

Terminal value comprises 78% of DCF enterprise value — intrinsic value estimate is highly sensitive to terminal growth and WACC assumptions; a conservative stress test (e.g., 1.5% terminal growth, 9% WACC) would likely produce intrinsic value near or below current price, eliminating the margin of safety
No tangible asset floor: price-to-book of 3.1x on a services business with no hard assets means liquidation value is well below market price and provides no downside protection
AI disruption risk is material and unquantified: BPO labor-arbitrage model is structurally vulnerable to automation over a 3-7 year horizon; WaveIX claims are qualitative and unverified by client-facing financial metrics in any filing or transcript
No special-situation catalyst: the TRGI block trade has already cleared; no spin-off, restructuring, forced selling, or index event that would create the technical mispricing I require
Insider selling in May-July 2026 (officer, director, CEO RSU withholding per narrative) at $30-35 range is a mild negative signal — not alarming but inconsistent with strong conviction from those closest to the business
FCF generation is lumpy and capital-intensive: Q2 FY2026 FCF was negative $5.1M; nine-month FCF only $9.5M (10-Q March 2026), well below annualized FY2025 figure, suggesting elevated CapEx cycle ($20-25M guided) is compressing near-term cash returns

Charlie Munger — 🟡 watch · 52/100 · medium confidence

IBEX is a BPO (business process outsourcing) operator — essentially a labor arbitrage and managed services business delivering customer experience work offshore. The business model is understandable in one paragraph: recruit and manage agents in lower-cost geographies (Philippines, Pakistan, Nicaragua, Jamaica, India), bill U.S. clients in dollars, and pocket the spread. The unit economics are readable. However, the quality lens demands I ask hard questions about moat durability, reinvestment returns, and whether this is a great business or merely a decent one at a fair price.

ROIC / Returns on Capital: The fact base shows ROIC of 23.8% and ROE of 23.9% for fiscal year 2025 (10-K filed 2025-09-11). These are genuinely impressive numbers for a services firm. FCF margin is thin at 4.9% but the asset-light nature of the business keeps invested capital low, which mechanically flatters ROIC. I must flag that capital intensity is rising — capex jumped from $8.9M in FY2024 to $18.4M in FY2025 and the 10-Q for Q2 FY2026 shows nine-month capex of $24.6M vs $13.2M in the prior period, with management guiding to the upper end of a $20–25M range. Higher capex will compress FCF margins and, over time, could pressure ROIC if the incremental returns on new delivery center investment are lower than the legacy base.

Moat Assessment — The Hard Question: This is where I become skeptical. BPO is not a natural moat business. Switching costs exist (client contracts, embedded workflows, data familiarity) but are moderate — clients routinely re-tender contracts. Pricing power is limited by competition from Concentrix, TTEC, Teleperformance, Conduent, and dozens of nearshore/offshore operators. Gross margins are not disclosed explicitly in the excerpts provided, but operating margin of 8.4% (10-K FY2025) and adjusted EBITDA margin of 12.9% are thin and consistent with a commoditized labor business rather than a franchise with pricing power. The narrative mentions SG&A declining from 18.3% to 16.8% of revenue, which is real operating leverage, but the underlying gross margin trajectory is unclear from the available data — I cannot confirm from the fact base whether gross margins are stable or eroding. Revenue CAGR of only 4.2% over three years (fundamentals block) is modest for a business claiming 'four consecutive quarters of double-digit organic growth'; this suggests prior years included declines (FY2024 revenue actually fell from $523M to $509M per the history table), so the recent acceleration may be recovery rather than structural re-rating.

AI and Disruption Risk — Cannot Be Ignored: The WaveIX AI platform claim is largely promotional from the earnings call transcript (Feb 2026 per the narrative). The existential question for BPO over a 3–10 year horizon is stark: generative AI and large language models are attacking the core product. If AI agents can handle a meaningful fraction of customer service interactions autonomously, the demand for human agents — IBEX's core revenue driver — could structurally decline. Management's framing of 'BPO 3.0' and AI as a tailwind (pairing AI with human agents) is plausible in the near term but does not resolve the long-term question of whether the human labor component shrinks. The narrative acknowledges this risk indirectly. I have no verifiable data from the fact base quantifying AI's actual current impact on agent headcount or revenue per agent. This is a genuine circle-of-competence question: I cannot reliably model the pace of AI displacement in CX, which makes long-term intrinsic value harder to anchor. A Munger-style thinker must honestly admit this uncertainty rather than dismiss it.

Capital Allocation — Mixed Signals: Management is running active buyback programs — $15M authorized in May 2025 (10-Q filed 2026-02-05), $20M authorized in May 2026 (8-K filed 2026-05-13). The large TRGI Purchase Agreement (10-K FY2025) involved buying back 3.56M shares for $70M ($45M cash + $25M convertible note), a significant transaction. This is broadly shareholder-friendly and the declining share count is real (diluted shares down from ~16.5M to ~14.7M per the narrative). However, the convertible note structure and the scale of the TRGI buyback relative to the company's FCF base ($27M) suggest capital was stretched. The subsequent share repurchase programs are more modest and fundable from operating cash flow. No serial dilution pattern is apparent; management appears owner-minded.

Balance Sheet: Total assets $295.8M, total liabilities $141.3M, equity $154.5M (10-Q Dec 2025). Cash of $15.5M. Debt-to-equity is listed as null in the fundamentals block; the 10-Q mentions HSBC Credit Facilities with net draws of $19.1M referenced in the nine-month cash flow discussion, and $7.5M in the six-month period. The balance sheet is not fragile but is not fortress-quality either — cash is modest relative to capex commitments and buyback ambitions. Current ratio of 1.83 is fine.

Valuation: DCF intrinsic value of $43.23/share vs current $35.34 implies 22% upside (valuation block). The DCF uses a 4.24% FCF growth rate (revenue CAGR) and 7.89% WACC, producing a base case that is reasonable but not conservative — 78% of the enterprise value sits in terminal value, meaning the thesis is highly dependent on the business being viable in year 6+. Given AI disruption risk, this terminal value dependency is uncomfortable. P/E of 12.8x and price-to-sales of 0.85x are genuinely undemanding. Price-to-FCF of 17.3x is fair but not cheap. The price is not obviously wrong for the current earnings stream, but for a Munger-quality buy I want to be paying a fair price for a great business, not a cheap price for a so-so business.

Inversion: How does this go wrong? (1) AI accelerates displacement of human CX agents faster than IBEX can pivot to AI-native services, causing secular revenue decline. (2) A major client (top client = 10% of revenue; top 10 = 39%) exits or dramatically cuts spend — client concentration is real. (3) Offshore labor cost inflation (especially Philippines and Pakistan) compresses the labor arbitrage margin. (4) BPO commoditization intensifies and contract re-pricing erodes already-thin margins. None of these is certain but all are plausible. The absence of an obvious, sturdy moat makes it difficult to dismiss these scenarios with confidence.

Summary: IBEX clears several Munger criteria — understandable business, decent ROIC, honest capital allocation, clean accounting, modest valuation. But it fails the most important one: I cannot identify a durable, defensible moat that will protect the franchise for a decade. BPO is a scale-and-execution business, not a franchise business. The AI disruption risk is material and unresolved. The thin margins leave little cushion. I would watch rather than buy — revisit if AI impact clarifies to be manageable, if gross margins demonstrate durability through a full cycle, or if the price drops to provide a more compelling margin of safety.

Key points

ROIC of 23.8% and ROE of 23.9% (FY2025, 10-K filed 2025-09-11) are genuinely strong numbers for a services firm, mechanically aided by low invested capital
Business model is transparent and understandable: offshore labor arbitrage for U.S. clients, dollar-denominated contracts, primarily Philippines/Pakistan/Nicaragua/Jamaica delivery
Revenue CAGR of only 4.2% over three years (fundamentals block) reflects a FY2024 revenue dip ($523M→$509M); recent double-digit growth may be cyclical recovery rather than structural re-rating
Capital allocation is broadly owner-minded: large TRGI buyback (3.56M shares for $70M per FY2025 10-K) and subsequent $15M and $20M repurchase programs reduce share count materially
DCF base case implies $43.23 intrinsic value vs $35.34 market price (22% upside), with P/E of 12.8x and price/sales of 0.85x — undemanding but 78% of EV in terminal value
Adjusted EBITDA margin stable at 12.8-12.9% (FY2024-2025 per 10-K 2025-09-11); SG&A declining as % of revenue showing real operating leverage
Balance sheet is adequate but not fortress-quality: $15.5M cash, active credit facility draws, buybacks stretching FCF of $27M

Red flags

No identifiable durable moat: BPO is a scale-and-execution business subject to competitive re-tendering; pricing power is structurally limited by dozens of global competitors
AI/automation is an existential risk to the core human agent model over a 3-10 year horizon; WaveIX platform claims are promotional and unquantified — no disclosed client ROI or agent displacement data in the fact base
Capex is accelerating materially ($8.9M FY2024 → $18.4M FY2025 → $24.6M nine-month FY2026 per 10-Q filed 2026-05-06), which will compress FCF margins and could pressure ROIC if incremental returns on new delivery center investment disappoint
Client concentration is real and unmitigated: top client = 10% of revenue, top 10 = 39% (per narrative); loss of one trophy client would be a significant revenue event
78% of DCF enterprise value sits in terminal value — the thesis is heavily dependent on the business remaining viable post-AI disruption in year 6+, which cannot be assumed with confidence
Multiple insider sells in May-July 2026 noted in the narrative (officer, director transactions at $30-31) — individually small but directionally notable
Operating margin of 8.4% (FY2025) is thin; gross margin trend is not explicitly disclosed in available filings excerpts, making it impossible to verify moat sustainability from the fact base alone

Forensic Short-Seller (Chanos/Einhorn-style) — 🟡 watch · 52/100 · medium confidence

IBEX is a profitable, cash-generating BPO with some genuine quality-of-earnings strengths but also a cluster of forensic signals worth monitoring. The core Chanos test — net income vs. operating cash flow — shows net income of $36.9M vs. OCF of $45.7M for FY2025 (10-K filed 2025-09-11), meaning OCF exceeds net income, which is a PASS on the core accrual test. FCF of $27.3M is positive and has been positive since FY2022. However, the YTD FY2026 data (10-Q filed 2026-05-06) raises new concerns: nine months ended March 31, 2026 shows OCF of $34.2M but capex of $24.6M, leaving FCF of only $9.5M, while capex is running at nearly 3x the prior-year nine-month pace ($13.2M). This capex surge is management-explained as offshore expansion investment, but it compresses near-term FCF and raises the question of whether reported earnings quality is deteriorating on a forward basis. The TRGI buyback ($70M at $45M cash + $25M convertible note, repaid Jan 2025 per 10-K filed 2025-09-11) was a large, complex related-party transaction that absorbed significant cash and required debt financing. Share count has been falling (diluted shares 16.5M to 14.7M YoY per earnings call narrative), so buybacks are genuinely accretive rather than treadmill dilution — this is a point in management's favor. Insider activity (officer sold 3,600 shares at $30.61 on Jun 16; director sold 1,030 shares May 29; CEO withheld 4,511 shares on RSU vesting Jul 6, per narrative) is modest in absolute dollar terms and not a clear cluster signal. The TRGI-related impairment of $1.1M on 'other non-current assets with a related party' (10-K 2025-09-11) — where management determined fair value no longer exceeded carrying value — is a minor but real related-party write-down worth flagging. The 47.5% Lake Ball LLC joint venture (equity method, 10-K 2025-09-11) is small ($0.4M investment) and appears clean. Adjusted EBITDA margin of 12.9% (10-K 2025-09-11) vs. GAAP operating margin of 8.35% represents a ~450bps gap, the bulk of which is D&A and SBC — not unreasonable for capital-light services but warrants tracking. Revenue recognition appears straightforward (services delivered, no percentage-of-completion or bill-and-hold flagged in filings). DSO data is not explicitly provided in the fact base, preventing a direct DSO trend test. AI/disruption: The WaveIX positioning is a narrative risk — if AI genuinely automates tier-1 contact center work, IBEX's core labor arbitrage model faces structural compression over a 5-10 year horizon. However, management's 'BPO 3.0' positioning (AI-assisted rather than AI-replaced) is a plausible near-term hedge. The kill question: this becomes a short if (1) capex-led FCF destruction persists into FY2027 without revenue acceleration, (2) India/offshore expansion fails to deliver margin improvement and OCF begins lagging net income structurally, or (3) AI commoditizes tier-1 CX faster than IBEX can move upmarket. The bear case is not yet falsified but is not yet confirmed.

Key points

Core Chanos accrual test PASSES: FY2025 OCF ($45.7M) exceeds net income ($36.9M) per 10-K filed 2025-09-11, suggesting earnings are real and conservative accrual accounting
FCF positive and improving trend: FY2021 -$4.7M, FY2022 +$14.1M, FY2023 +$22.9M, FY2024 +$27.0M, FY2025 +$27.3M — consistent improvement (fundamentals history)
Share buybacks genuinely accretive: diluted share count down ~10% YoY (narrative, Q2 FY2026 call), not merely offsetting SBC dilution
TRGI buyback ($70M, Nov 2024) was large and complex with related-party dimensions but convertible note repaid Jan 2025 (10-K 2025-09-11); balance sheet not currently stressed
Net cash position of $14-15.5M, current ratio 1.83x (fundamentals), no debt wall flagged in available filings
Insider selling modest and not clustered at high prices; officer sale at $30.61 (Jun 16) was below current price of $35.34

Red flags

Capex surge in YTD FY2026: nine months ended Mar 31, 2026 capex of $24.6M vs. $13.2M prior-year period (10-Q filed 2026-05-06), nearly doubling — FCF compressed to $9.5M YTD vs. $4.5M prior year despite higher OCF; if this pace continues it could flip FCF negative
TRGI-related party impairment: $1.1M write-down on 'other non-current assets with a related party' in FY2025 (10-K 2025-09-11) — small but signals prior overvaluation of related-party asset
GAAP-to-adjusted gap: operating margin 8.35% vs. adjusted EBITDA margin 12.9% (10-K 2025-09-11) is ~450bps; SBC and D&A add-backs are recurring, not one-time; adjusted metrics flattering reported performance
DSO trend cannot be verified — fact base lacks explicit receivables-to-revenue ratio over time; this is a missing data point that prevents a complete accrual quality test
AI disruption risk is real over 5-10 year horizon: if LLM-based agents commoditize tier-1 CX work, offshore labor arbitrage collapses faster than IBEX can migrate upmarket; WaveIX claims are qualitative and unquantified
Derivative losses emerging in FY2026: unrealized losses on cash flow hedges of -$5.2M in nine months ended Mar 31, 2026 (10-Q filed 2026-05-06) vs. gains in prior period; PHP hedge book ($88.9M notional, 10-K 2025-09-11) creates earnings volatility risk

Paul Singer — 🟡 watch · 52/100 · medium confidence

IBEX is a small-cap BPO operator (~$473M market cap) with genuine operational momentum but limited activist applicability. The self-help gap here is narrow-to-moderate rather than the wide, structural, conglomerate-discount situation Elliott typically targets. The company operates as a single reportable segment (confirmed in both 10-K filed 2025-09-11 and 10-Q filed 2026-05-06), eliminating any sum-of-the-parts opportunity. There is no conglomerate discount to arbitrage. Capital allocation has been reasonable but not obviously destructive: the TRGI block purchase of 3,562,341 shares for $70M (10-K filed 2025-09-11) was a significant transaction with a related-party overhang now largely resolved, share repurchase programs have been consistent ($15M in May 2025, $20M in May 2026 per the 8-K filed 2026-05-13), and FCF generation is positive though modest ($27.3M in FY2025 per 10-K). The DCF suggests ~22% upside to intrinsic value ($43.23 base vs. $35.34 current price), which is a real but not extreme discount. The floor exists: net cash position (~$15.5M cash, no disclosed net debt per fundamentals block), current ratio of 1.83, and positive operating cash flow ($45.7M in FY2025). The primary activist concern is governance and control structure. IBEX was previously controlled by TRGI (a related party), and the November 2024 TRGI Purchase Agreement (10-K filed 2025-09-11) whereby IBEX repurchased TRGI's 3,562,341 shares for $70M ($45M cash + $25M convertible note, repaid January 2025) marks a pivotal shift. This overhang appears largely cleared, but IBEX is incorporated in Bermuda (noted in 8-K filings), which limits the applicability of US shareholder-rights tools (written consent, proxy access norms, Section 13D timing). The board composition and independence details are not fully disclosed in this fact base — a critical gap. Related-party dealings were material (the $70M TRGI transaction, prior related-party revenue/payables per 10-K 2024-09-12), and the impairment of $1.1M in non-current assets with a related party (10-K 2025-09-11) signals prior allocation that was not arm's-length. Insider selling in May-July 2026 (director, officer, CEO RSU withholding per narrative) is a modest negative signal. The AI/WaveIX thesis is qualitative and unproven in financial terms — no quantified margin benefit or client premium pricing is disclosed. The primary lever an activist could pull is capital return acceleration (the company generates ~$27M FCF annually but market cap is $473M — 5.8% FCF yield — while spending only $15-20M per year on buybacks), and potentially a sale-of-company outcome given the modest scale and private equity appetite for BPO assets at 7-9x EBITDA. At ~$80-82M guided Adj. EBITDA for FY2026 (per earnings call narrative), a 7-8x multiple implies $560-656M enterprise value, suggesting 20-40% upside vs. current market cap. This is real but not dramatic. The key issue is forceability: Bermuda incorporation, unclear board composition, and no identified external shareholder catalyst make this a 'watch' rather than a conviction activist target.

Key points

Single reportable segment (confirmed 10-K 2025-09-11 and 10-Q 2026-05-06) eliminates sum-of-the-parts opportunity — no conglomerate discount to arbitrage
TRGI controlling-shareholder overhang substantially cleared via November 2024 block repurchase of 3.56M shares for $70M (10-K 2025-09-11); capital structure simpler post-transaction
DCF base case implies ~22% upside ($43.23 intrinsic vs. $35.34 price); at guided ~$80-82M FY2026 Adj. EBITDA, a 7-8x EV/EBITDA acquisition multiple implies $560-656M EV vs. ~$458M current EV — real but not extreme gap
Capital return activity accelerating: $15M buyback (May 2025), $20M buyback authorized May 2026 (8-K 2026-05-13), reducing share count ~10% YoY; FCF yield ~5.8% suggests room for more aggressive return
Net cash position (~$15.5M per fundamentals) and current ratio of 1.83 provide a genuine downside floor; no near-term debt maturity stress disclosed
India expansion and HealthTech vertical growth are genuine organic catalysts but require capital (CapEx guided $20-25M FY2026 per earnings narrative), limiting near-term FCF for return
Bermuda incorporation is a structural limitation on US-style activist tools (written consent, proxy access, hostile tender norms)

Red flags

No lever identified: Bermuda incorporation limits standard activist playbook; board independence and staggered-vs-annual election details not present in this fact base — critical gap for assessing forceability
Prior related-party transactions with TRGI were extensive and not fully arm's-length; $1.1M impairment on related-party non-current assets recognized FY2025 (10-K 2025-09-11) indicates prior capital allocation was impaired
Single segment structure eliminates any SOTP opportunity; no hidden parts that could be separated at higher multiples
Multiple insider sales in May-July 2026 at prices below current intrinsic value estimate suggest insiders not fully aligned with long thesis
No disclosed quantified return on AI/WaveIX investment — claims of leadership are qualitative only; risk of overspending on technology with no demonstrated pricing premium
CapEx front-loaded in FY2026 (9-month capex $24.6M vs. full-year FY2025 $18.4M per 10-Q 2026-05-06), compressing near-term FCF and limiting buyback firepower
Company is already executing buybacks and has raised guidance — partially self-helped; remaining discount may not be forceable without an external catalyst or larger holder willing to push for a sale

Terry Smith (Fundsmith) — 🟡 watch · 52/100 · medium confidence

IBEX Ltd is an established, profitable BPO/contact-centre outsourcer with a multi-year operating history and disclosed margins, so the quality lens can be applied. The business passes some Fundsmith screens — notably ROIC of ~24% (fundamentals block) and improving cash conversion — but fails others that matter most to my framework: margins are thin and volatile for a 'quality' business, the model is labour-intensive and structurally capital-consumptive relative to what I would consider asset-light, and the moat is shallow in a commoditised industry facing genuine AI-driven disruption risk. Revenue CAGR of only 4.2% over three years and FCF margins of roughly 5% do not suggest the kind of compounding engine Fundsmith seeks. That said, the valuation (P/E 12.8x, P/FCF 17.3x, price-to-sales 0.85x) is genuinely modest, and the DCF base case of $43.23 implies ~22% upside from current price of $35.34. I land at 'watch' — not a clear avoid, but not a Fundsmith-quality compounder either.

Key points

ROIC of ~23.8% (fundamentals block) and ROE of ~23.9% clear the 20%+ threshold Smith prizes in a single year, but must be viewed against thin operating margins (8.35%) and FCF margins (~4.9%) that are uncharacteristic of a durable quality compounder; the ROE is partly flattered by a relatively small equity base rather than exceptional capital productivity
Cash conversion is adequate: operating cash flow of $45.7M vs net income of $36.9M (FY2025, 10-K filed 2025-09-11) implies solid accruals quality; FCF of $27.3M vs net income of $36.9M gives conversion ratio ~74%, acceptable but not exceptional — Fundsmith prefers FCF > net income
Revenue history shows 4.2% 3-year CAGR (fundamentals block), with FY2024 revenue actually declining to $508.6M before recovering to $558.3M in FY2025; this is not the steady, resilient compounding pattern Smith demands
Management commentary (Q2 FY2026 earnings call, per narrative) reports four consecutive quarters of double-digit organic growth, HealthTech vertical up 35.1% YoY, and raised full-year guidance to $620-630M — this is a positive acceleration, but one year of re-acceleration does not establish the multi-cycle durability Fundsmith requires
Share buybacks are shareholder-friendly: the TRGI Purchase Agreement (10-K, 2025-09-11) involved repurchasing 3.56M shares for $70M; subsequent $15M and $20M authorisations (10-Q 2026-05-06; 8-K 2026-05-13) demonstrate capital discipline; diluted share count fell from ~16.5M to ~14.7M YoY per narrative, enhancing per-share metrics
Balance sheet is clean by BPO standards: no debt-to-equity ratio disclosed (null in fundamentals, indicating minimal or no net debt), net cash position of ~$14-15M (narrative + fundamentals), current ratio 1.83 — leverage is not a red flag here
DCF intrinsic value of $43.23/share (valuation block, base case) versus current price of $35.34 implies 22% margin of safety; bear case of $33.67 is only marginally below current price, limiting downside protection — not the wide margin Smith would want on a fragile moat
WaveIX AI platform positioning (narrative, Q2 earnings call) is qualitatively interesting but unverified; no quantified client ROI or pricing premium disclosed — this is management commentary, not a demonstrated moat

Red flags

Thin margins are the central Fundsmith disqualifier: 8.35% operating margin and 4.9% FCF margin are at the lower bound of what Fundsmith would consider — iconic compounders in the Fundsmith portfolio (consumer staples, healthcare, software) typically run 20-40%+ operating margins; these margins leave little buffer against labour cost inflation, FX headwinds, or pricing pressure
Labour-intensive model with material capex: CapEx of $18.4M in FY2025 rising to an expected $20-25M in FY2026 (upper end per narrative), against FCF of only $27.3M — capex is consuming ~40% of operating cash flow; the 10-Q (2026-02-05) shows H1 FY2026 capex of $19.4M already exceeding full-year FY2024 ($8.9M), indicating accelerating capital intensity that is incompatible with the asset-light compounder model
Structural AI disruption risk is high and not fully priced in: BPO contact-centre work — particularly tier-1 customer service — is among the most exposed categories to large language model automation; IBEX's 'WaveIX' narrative (Q2 earnings call) acknowledges the threat by positioning as an AI-augmented provider, but the underlying economics of human-agent labour arbitrage could be fundamentally undermined within 5-7 years; this is not a business where AI enhances the moat — it threatens the core value proposition
Shallow competitive moat: the 10-K (2025-09-11) discloses a single operating segment, single CODM reporting structure, with no disclosed proprietary technology, brand, or IP beyond the WaveIX claim; switching costs in BPO are lower than in software; pricing power is limited in a competitive outsourcing market with large peers (Accenture, Teleperformance, TTEC)
FCF conversion below net income at 74% (FY2025) and negative free cash flow in several recent quarters (H1 FY2026: $2.9M FCF per 10-Q 2026-02-05; Q2 FY2026: -$5.1M per narrative) due to capex surges — the episodically negative FCF profile is inconsistent with Fundsmith's preference for businesses that reliably convert earnings to cash
Insider selling pattern (narrative): officer sold 3,600 shares at $30.61 (Jun 16, 2026), director sold 1,030 shares (May 29, 2026); while individually small, the pattern of selling near current price levels is a mild negative signal; CEO RSU withholding on vesting (Jul 6) is neutral but reduces net insider accumulation
Revenue concentration: top 25 clients = 79% of revenue (narrative, Q2 call); top client = 10% — moderate but not de-risked; loss of 2-3 major clients would materially impair financials in a way that Fundsmith staples businesses (where no single customer is >2-3% of revenue) would not face

AI & Disruption Referee (Christensen-style) — 🟡 watch · 48/100 · medium confidence

IBEX is a BPO/contact center operator whose core product is human labor at scale — exactly what generative AI is most directly attacking. The company's revenue model pays agents (mostly offshore) to handle customer service interactions, digital acquisition, back-office work, and increasingly revenue cycle management. On a 3-10 year horizon, the Christensen disruption framework lights up red: the 'job to be done' (handling inbound CX queries, processing transactions, acquiring leads, resolving healthcare billing) is precisely what large language models and autonomous AI agents are being trained to do cheaper and faster. However, IBEX earns a partial reprieve because management is not in denial — the WaveIX AI platform framing and the appointment of a Chief AI & Digital Officer (Mike Darwall, noted in the narrative Q2 FY2026 earnings call commentary) suggest the company is attempting to become the AI orchestration layer rather than be replaced by it. The key question is whether this pivot is genuine infrastructure or marketing veneer. Based on available evidence, it is too early to confirm either, warranting a 'watch' rather than 'avoid' — but the structural threat is real and the bull case requires IBEX to win on AI rather than merely survive it. The 4.2% revenue CAGR (fundamentals block) and sub-5% FCF margins give limited financial buffer if AI-native competitors or self-service adoption accelerates. The cheap multiple (P/E 12.8x, P/S 0.85x per fundamentals) may be the market partially pricing in this disruption risk — the classic 'melting ice cube' trap the other lenses miss.

Key points

Core job-to-be-done is human-staffed CX and BPO — generative AI (voice agents, LLM-powered chat, autonomous ticket resolution) directly attacks this value proposition. Companies like Cogito, PolyAI, Forethought, and Sierra AI are building AI-native contact center replacements. Hyperscalers (Amazon Connect + Bedrock, Google CCAI, Microsoft Copilot for Service) are bundling AI CX capabilities into existing cloud relationships, potentially disintermediating outsourced BPO.
IBEX's WaveIX AI platform is disclosed in the Q2 FY2026 earnings call commentary (narrative) as combining client-facing AI agents with human agents and using AI for internal hiring/training optimization. This dual-sided deployment (external CX plus internal efficiency) is the right strategic posture — if genuine, it could lower cost-per-interaction and expand margins. However, the fact base contains no quantified client ROI, no disclosed revenue from AI-enabled contracts versus traditional, and no evidence clients are paying a premium for AI differentiation versus traditional BPO.
The HealthTech vertical (now 17.4% of revenue per narrative, growing 35% YoY) and revenue cycle management entry in India introduce workflow complexity (clinical documentation, credentialing, billing adjudication) that is harder to fully automate than tier-1 voice support — this is a partial moat against pure AI displacement. However, major health IT vendors (Epic, Oracle Health) and AI startups (Abridge, Cohere Health, Waystar) are also attacking these workflows.
Mix shift away from legacy telecom (now <10% per narrative) toward HealthTech and digital services is a positive signal — telecom Tier-1 support is the most commoditized, most AI-replaceable work. IBEX is migrating toward stickier, more complex verticals, which buys time but does not eliminate the structural threat.
Offshore labor arbitrage (Philippines, Pakistan, Nicaragua, Jamaica noted in 10-Q and 10-K filings) remains a cost advantage today, but AI democratizes low-cost output globally — the Philippines wage advantage narrows if an AI agent does the same work at near-zero marginal cost. The offshore mix (52.3% of revenue per narrative) is simultaneously the highest-margin segment and the most exposed to volume loss if AI adoption accelerates.
The falsifiable bull case: if IBEX's WaveIX platform generates measurable take-rate expansion, wins net-new clients specifically citing AI differentiation, and sustains FCF margins above 6% as AI adoption grows, the company is successfully becoming the AI layer. The falsifiable bear case: if revenue per agent-equivalent falls, if customer self-service rates rise materially, or if a hyperscaler (Amazon, Google) offers competitive AI-native CX at a price that forces IBEX to cut rates to retain clients, the disruption is confirmed. Neither has been definitively proven yet — hence 'watch.'
Capital expenditure is rising (FY2025 capex $18.4M vs $8.9M in FY2024 per 10-K filed 2025-09-11; H1 FY2026 capex $19.4M per 10-Q filed 2026-02-05, already exceeding full FY2025), partly to fund offshore expansion and India entry. This is consistent with investing ahead of growth, but also means the company is doubling down on physical infrastructure (delivery centers, equipment) at the same moment AI threatens to commoditize the labor those centers house — an execution risk if the AI timeline accelerates faster than the India/HealthTech ramp delivers returns.

Red flags

Revenue rests on human labor at scale — 13,000+ agents performing CX interactions is precisely the unit of value that LLMs and voice AI are becoming competent at, following the classic Christensen pattern of 'good enough' disruption from below. Tier-1 support (password resets, order status, billing questions) is already being replaced by AI at client-side; IBEX must migrate clients to higher-complexity work faster than AI commoditizes current work.
No disclosed evidence of pricing power improvement from AI — the narrative notes management claims AI differentiation drives new logo wins, but no take-rate data, no AI-attributable revenue line, and no client case studies with quantified outcomes are present in the fact base. Qualitative 'AI leadership' claims without quantification are a classic management-in-denial warning sign.
Hyperscaler bundle risk is not acknowledged in management commentary (per available narrative). Amazon, Google, and Microsoft each have AI-native contact center offerings integrated into their cloud platforms, with distribution advantages IBEX cannot match. If a large client's IT organization standardizes on AWS Connect or Google CCAI, IBEX loses the engagement without a competitive bid.
The $20M share repurchase announced May 2026 (8-K filed 2026-05-13) and prior $15M program (noted in 10-Q filed 2026-05-06) signal management confidence, but buybacks at sub-$40 are sensible only if the FCF stream is durable. If AI erodes volume, the FCF base that funds buybacks shrinks — the buyback itself could become a capital allocation mistake if disruption accelerates.
Multiple insider sales in May-July 2026 (noted in narrative) at $30-31 levels, while not individually large, create a pattern of insiders not aggressively buying at what management publicly describes as deeply undervalued prices. This is a soft signal, not conclusive, but directionally inconsistent with management's bullish AI positioning rhetoric.

Walter Schloss — 🔴 avoid · 32/100 · high confidence

IBEX does not meet Schloss deep-value criteria on any of the primary screens. The stock trades at 3.06x book value (fundamentals block) and 0.85x price-to-sales, anchored by an asset-light BPO services business whose balance sheet carries very little in the way of hard, appraisable tangible assets. Tangible book value is further undermined by the fact that the business is predominantly people and contracts — the kind of intangible-heavy, earnings-dependent franchise I avoid. The 52-week price range is $25.94 to $42.99, and the current price of $35.34 sits in the upper half of that range (17.8% off the 52-week high per the fact base), not at a depressed low that would signal the disfavor I require. The DCF intrinsic value of $43.23 per share (valuation block) implies 22% upside, but a Schloss bargain is never built on a DCF — it is built on assets that can be counted and appraised, and those are thin here. On the balance sheet: total assets of $295.8M vs. total liabilities of $141.3M yields stockholders' equity of $154.5M (fundamentals, period ending 2025-12-31). With 13.3M shares outstanding, that is roughly $11.60 book per share vs. a $35.34 price — a 3x premium to book. Worse, the asset base is almost certainly dominated by operating lease right-of-use assets, receivables, and goodwill/intangibles rather than plant, inventory, or cash with independent liquidation value; the 10-K and 10-Q filings cite leasehold improvements, furniture, and computer equipment with 3-5 year lives, not the durable hard assets I anchor to. Cash is only $15.5M (fundamentals, December 2025). While there is no debt-to-equity figure in the fact base, the 10-Q (filed 2026-05-06) references net draws from HSBC Credit Facilities, confirming debt usage. Free cash flow is positive ($27.3M for FY2025 per the 10-K filed 2025-09-11) but thin as a percentage of revenue (4.9%), and the 10-Q for the period ending March 2026 shows nine-month free cash flow of only $9.5M with elevated capex of $24.6M, suggesting FCF is lumpy and investment-intensive. The TRGI share buyback for $70M (10-K, 2025-09-11) — $45M cash and $25M convertible note — was a large capital outlay that compressed cash reserves. Insider activity in May-July 2026 (director sold 1,030 shares, officer sold 3,600 shares at $30.61, CEO withheld shares on RSU vesting per the narrative) skews toward selling, not buying — the opposite of the insider alignment I want. The P/E of 12.84x is undemanding for a growing BPO, but Schloss never bought on earnings; he bought on assets, and those are not here at an attractive price. AI and automation pose a genuine long-run structural threat to the contact-center BPO model — the core product (human agents handling customer interactions) is precisely what AI is targeting — adding further risk to the thesis. The company's WaveIX positioning is acknowledged in management commentary but is unquantified and unverifiable from the filings.

Key points

Price-to-book of 3.06x is far above the sub-1x or near-book threshold Schloss required; no margin of safety in hard assets
Current price of $35.34 is in the upper half of the 52-week range ($25.94–$42.99), not beaten-down or out of favor
Balance sheet is asset-light: total assets $295.8M with a large portion likely in operating lease ROU assets, receivables, and modest PP&E (3-5 year useful lives per 10-K filed 2025-09-11), not independently appraisable tangibles
Cash position of only $15.5M (Dec 2025) with active HSBC credit facility drawdowns; leverage risk acknowledged in 10-Q (filed 2026-05-06)
Insider activity in May-July 2026 skews to selling (officer, director) with no documented insider buying — misaligned with Schloss alignment criterion
FCF positive ($27.3M FY2025) but lumpy; nine-month FCF only $9.5M through March 2026 due to elevated capex of $24.6M (10-Q filed 2026-05-06)

Red flags

3.06x price-to-book with no tangible asset floor — primary Schloss disqualifier
Stock near mid-range of 52-week band, not at a distressed low that creates statistical cheapness
Thesis depends on earnings growth, AI positioning, and vertical mix shift — exactly the kind of forward narrative Schloss avoided
Multiple insiders selling in May-July 2026 at prices near or below current levels, no insider buying documented
TRGI buyback consumed $45M cash (10-K 2025-09-11), thinning the balance sheet cushion
AI and automation represent a structural threat to the core human-agent BPO model over a 3-10 year horizon, undermining any asset-based recovery thesis

Fact base appendix

Price

last_close: 35.34
as_of: 2026-08-02
high_52w: 42.99
low_52w: 25.94
range_source: provider
pct_below_52w_high: -17.79

Fundamentals

last_price: 35.34
market_cap: 473171371
fifty_two_week_high: 42.99
fifty_two_week_low: 25.94
beta: 0.7179987
currency: USD
exchange: NASDAQ NMS - GLOBAL MARKET
sector: Professional Services
industry: Professional Services
price_source: finnhub
bars: 1
entity: IBEX LIMITED
fiscal_year: 2025
revenue: 558273000
revenue_period: 2025-06-30
net_income: 36864000
net_income_period: 2025-06-30
operating_income: 46611000
operating_income_period: 2025-06-30
operating_cash_flow: 45668000
operating_cash_flow_period: 2025-06-30
capex: 18375000
capex_period: 2025-06-30
total_assets: 295797000
total_assets_period: 2025-12-31
total_liabilities: 141282000
total_liabilities_period: 2025-12-31
current_assets: 158524000
current_assets_period: 2025-12-31
current_liabilities: 86505000
current_liabilities_period: 2025-12-31
stockholders_equity: 154515000
stockholders_equity_period: 2025-12-31
cash_and_equivalents: 15460000
cash_and_equivalents_period: 2025-12-31
shares_outstanding: 13315077
operating_margin: 0.0835
net_margin: 0.066
roe: 0.2386
debt_to_equity: None
current_ratio: 1.8325
roic: 0.2383
free_cash_flow: 27293000
fcf_margin: 0.0489
pe_ratio: 12.84
price_to_fcf: 17.34
price_to_sales: 0.85
revenue_cagr: 0.0424
revenue_cagr_years: 3
fundamentals_source: edgar_companyfacts
price_to_book: 3.06
earnings_yield: 0.1018
peg: 3.03

Filings reviewed

8-K (2026-05-13) https://www.sec.gov/Archives/edgar/data/1720420/000172042026000014/ibex-20260511.htm
10-Q (2026-05-06) https://www.sec.gov/Archives/edgar/data/1720420/000172042026000011/ibex-20260331.htm
8-K (2026-05-06) https://www.sec.gov/Archives/edgar/data/1720420/000172042026000010/ibex-20260506.htm
10-Q (2026-02-05) https://www.sec.gov/Archives/edgar/data/1720420/000172042026000006/ibex-20251231.htm
10-K (2025-09-11) https://www.sec.gov/Archives/edgar/data/1720420/000172042025000027/ibex-20250630.htm
10-K (2024-09-12) https://www.sec.gov/Archives/edgar/data/1720420/000172042024000042/ibex-20240630.htm

Other sources

[news] Ibex Ltd (IBEX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
[news] IBEX (IBEX) officer sells 3,600 shares at $30.61 average price - Stock Titan
[news] Earnings call transcript: IBEX Q3 2026 sees revenue beat, stock surges 15% - Investing.com
[news] IBEX Ltd (IBEX) officer transfers 200 shares in divorce-related agreement - Stock Titan
[news] Ibex Ltd (IBEX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[news] Ibex Ltd (IBEX) Valuation: PE, PB & Fair Value Analysis - TradingKey
[news] Ibex Ltd Earnings Call Highlights Growth And AI - The Globe and Mail
[news] IBEX (IBEX) CEO has 4,511 shares withheld on RSU vesting - Stock Titan
[news] IBEX|Ibex Ltd|Price:35.340|Chg%:-0.125 - TradingKey
[news] Insider Sale: Director at $IBEX Sells 1,030 Shares - Moomoo
[news] IBEX Limited: Shareholders Board Members Managers and Company Profile | BMG4690M1010 - marketscreener.com
[discussion] $IBEX shows another clear impulsive sequence from the 03.30.2026 low. More upside remains on track
[discussion] Daily Technical Video Group 1 is ready for viewing at www.elliottwave-forecast.com
We said that $I
[discussion] [Bullish] Update — Group 1: All instruments are updated on the 4-hour time frame. $IBEX shows a clea
[discussion] Live Session — Members reviewed every instrument and what the structure suggests comes next in this
[discussion] $IBEX The stock IBEX, not whatever the other thing talked about here is, has just pivoted off the lo
[discussion] $IBEX — latest view suggests a possible new high against last week’s low, which would complete a 5‑w
[discussion] $IBEX — aiming for new high against last week’s low; 5‑wave advance from March lows nearly complete.
[discussion] $IBEX — latest view suggests a possible new high against last week’s low, which would complete a 5‑w
[discussion] $IBEX — latest view suggests a possible pullback toward the hourly 🔵 BlueBox area, where buyers may
[discussion] [Bullish] Live Session concluded — the next opportunity across Indices is approaching

Market rema

[discussion] $IBEX latest H1 chart update supports more upside as corrective pullbacks are very likely to finish
[discussion] 📊 Group 1 New York charts are live @ https://elliottwave-forecast.com?fpr=ewf76

$IBEX — Wave (iii

[discussion] 📊 $IBEX cycle from 05.18.2026 is nearly matured and is expected to correct lower in 3 or 7 swings ag
[discussion] $IBEX Share Price: $29.76

Contract Selected: Dec 18, 2026 $30 Calls

Buy Zone: $2.98 – $3.68 Target

[discussion] $IBEX Valuation measures for IBEX. This stock is cheaper than dirt. I’m loaded:

https://finance.yah

[earnings_call] IBEX Limited Q2 2026 Earnings Call

Data gaps

Dataset completeness: 27 of 27 source documents were dropped to fit the prompt budget — the council did not see them.

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →